Vaccines and Global Health: The Week in Review is a weekly digest — summarizing news, events, announcements, peer-reviewed articles and research in the global vaccine ethics and policy space. Content is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage. You are viewing the blog version of our weekly digest, typically comprised of between 30 and 40 posts below all dated with the current issue date

.Request an Email Summary: Vaccines and Global health : The Week in Review is published as a single email summary, scheduled for release each Saturday evening before midnight (EDT in the U.S.). If you would like to receive the email version, please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.
.
pdf versionA pdf of the current issues is available here: Vaccines and Global Health_The Week in Review_26 July 2014

Twitter:  Readers can also follow developments on twitter: @vaxethicspolicy.
.
Links:  We endeavor to test each link as we incorporate it into any post, but recognize that some links may become “stale” as publications and websites reorganize content over time. We apologize in advance for any links that may not be operative. We believe the contextual information in a given post should allow retrieval, but please contact us as above for assistance if necessary.
.
Support:  If you would like to join the growing list of individuals who support this service and its contribution to their roles in public health, clinical practice, government, IGOs/NGOs, research, industry and academia, please visit this page at The Wistar Institute, our co-founder and fiduciary. Thank you…
.

.
David R. Curry, MS
Executive Director
Center for Vaccine Ethics and Policy
a program of the
– Division of Medical Ethics, NYU Medical School
– The Wistar Institute Vaccine Center
– Children’s Hospital of Philadelphia Vaccine Education Center
Associate Faculty, Division of Medical Ethics, NYU Medical School

Cholera, OCV: Haiti, South Sudan

PAHO/WHO: Haiti to launch cholera vaccination with PAHO/WHO support
Port-au-Prince, Haiti, 23 July 2014 (PAHO/WHO)
Excerpt
Haiti is set to vaccinate 200,000 people in three departments against cholera starting in August, with support from the Pan American Health Organization/World Health Organization (PAHO/WHO).
The campaign will be carried out in the Artibonite (Gonaives and Ennery), Central (Lascahobas, Saut d’Eau, Savanette and Mirebalais), and West (Arcahaie) departments, which were chosen by the Ministry of Public Health and Population (MSPP) because they are considered high-risk zones…

PAHO/WHO’s representative in Haiti, Jean-Luc Poncelet, noted that vaccination is one of a series of measures implemented by Haitian health authorities with support from PAHO/WHO and other international partners. Other key measures include timely treatment for people sickened by the disease, improved access to potable water and adequate sanitation, the promotion of community participation and strengthened epidemiological surveillance…

Last week, PAHO/WHO shipped 400,000 doses of oral cholera vaccine (OCV) to Haiti. UN Secretary-General Ban Ki-moon formally presented the vaccines to Minister of Health Florence Guillaume. They are being kept at Haiti’s PROMESS warehouse, which has been managed by PAHO/WHO since 1992.

Financed by the UN’s Central Emergency Response Fund (CERF), the vaccines are from a global stockpile created by the World Health Assembly in 2011 to provide an additional tool for controlling cholera epidemics around the world. Besides Haiti, the global stockpile—for which WHO serves as secretariat—has also provided vaccines to the Democratic Republic of Congo, South Sudan, Guinea and Ethiopia. The stockpile is also supported by the International Federation of Red Cross and Red Crescent Societies, Doctors without Borders and UNICEF.

PAHO/WHO is also assisting efforts to fight cholera in Haiti and the Dominican Republic along with other members of the Regional Coalition for Water and Sanitation to Eliminate Cholera in Hispaniola. The Coalition, for which PAHO/WHO serves as secretariat, provides technical expertise on cholera control and elimination and is seeking to mobilize resources to support the two countries’ national plans to eliminate cholera by 2022…

:: Oral cholera vaccine stockpile (WHO)
:: Regional Coalition for Water and Sanitation to Eliminate Cholera in Hispaniola

.

WHO: Humanitarian Health Action [to 26 July 2014]
:: The cholera outbreak and health situation in South Sudan
25 July 2014 –“General security situation remained calm in most parts of the country, with isolated incidents and clashes in Upper Nile, Jonglei and Unity states. No new significant displacements have been reported. Efforts to contain the cholera outbreak continue. Health facilities had recorded 5,141 (CFR 2.2%) cases by 21 July 2014. Acute Watery Diarrhoea (AWD) is the leading cause of morbidity among Internally Displaced People (IDP)…
:: Read the latest health situation report
pdf, 894kb
:: Read the latest Health Cluster bulletin
pdf, 883kb

POLIO [to 26 July 2014]

POLIO [to 26 July 2014]

Report: Polio – Outbreak in the Middle East :: War in Syria Opens the Door to an Old Enemy
WHO, UNICEF
July 2014 12 pages
Excerpt from WHO announcement
Amman/ Cairo, 22 July 2014 – In a report released today, WHO and UNICEF announced completion of the first phase of the biggest polio vaccination campaign ever undertaken in the history of the Middle East; 25 million children under the age of five have been reached in seven countries in 37 rounds.

“Despite immense challenges and the desperate conditions around the region, children were vaccinated from three to six times. This gives a glimpse of hope and is largely thanks to thousands of unsung heroes: committed health workers and volunteers who undertook such a formidable task all over the region and inside Syria braving dangers to provide the polio vaccination to children,” said Maria Calivis, UNICEF’s Regional Director for the Middle East and North Africa.

The report attributes the return of polio to Syria after 14 years to the following factors: disruption of routine immunization; severe damage to Syria’s health infrastructure; continuous population displacement within Syria and across its borders; and missed children…

“Polio has forced its way back to Syria, adding to what was already a humanitarian disaster. We got to a point where we had to work with very limited resources to defeat what had been a long forgotten enemy in this region: one that does not know borders or checkpoints and can travel fast, infecting children not just in war torn Syria but across the region” said Chris Maher, WHO Manager for Polio Eradication and Emergency Support…

The report says that a number of critical actions must be undertaken to end the polio spread in the region:
:: Grant immediate and unhindered access to hard-to-reach children under the age of five inside Syria.
:: Guarantee the safe passage of health workers and protect medical vehicles and other cold chain equipment inside Syria.
:: Raise awareness on polio and the need to vaccinate all children under the age of five around the region multiple times.
:: Secure funding to undertake repeated vaccination rounds by the end of 2014…

.

GPEI Update: Polio this week – As of 23 July 2014
Global Polio Eradication Initiative
Editor’s Excerpt and text bolding
Full report: http://www.polioeradication.org/Dataandmonitoring/Poliothisweek.aspx
:: Polio vaccination campaigns reaching more than 25 million children multiple times in the Middle East since October have helped slow the outbreak: new report from UNICEF and WHO emphasises that the second phase of outbreak response focuses on reaching those children who continue to be missed.
:: In the Horn of Africa, further efforts are on to intensify the outbreak response, following confirmation of new cases from Somalia last week. These cases underscore the risk that ongoing low-level poliovirus transmission continues to pose to children across the region, and of the urgent need to fully stop the outbreak rapidly completely.
Afghanistan
:: Khost province borders Pakistan, where communities displaced by military action have been leaving North Waziristan, Pakistan. Health authorities in surrounding districts of Pakistan and across the border in Afghanistan have been vaccinating displaced children: more than 35,000 displaced children under the age of 10 are reported to have received a dose of bivalent oral polio vaccine (bivalent OPV) as they entered the Afghan provinces of Paktyka and Khost.
Nigeria
:: One new circulating vaccine-derived poliovirus type 2 (cVDPV2) case was reported in the past week, with onset of paralysis on 13 June from Borno. The total number of cVDPV2 cases for 2014 is now 14. It is the most recent cVDPV2 case in the country.
Pakistan
:: Five new WPV1 cases were reported in the past week, three from Federally Administered Tribal Areas (FATA – two from North Waziristan and one from South Waziristan), one from Khyber Pakhtunkhwa (KP) and one from Gadap, greater Karachi, Sindh. This brings the total number of WPV1 cases in the country to 99 for 2014. The case from South Waziristan is the most recent in the country, with onset of paralysis on 28 June.
:: In order to protect those displaced by the military action in North Waziristan, people of all ages continue to be vaccinated against polio at transit points within the country (over 394,000 vaccinated to date) and during several rounds of house-to-house immunization campaigns in the host communities (over 500,000 vaccinated in the first two rounds, with a third round just concluded)
Central Africa
:: The entire population of Equatorial Guinea, regardless of age, will be vaccinated in a campaign starting on 26 July. A house-to-house search for acute flaccid paralysis (AFP) cases will be conducted during the campaign; a similar search is currently taking place in Gabon. Cameroon, the Central African Republic (CAR), the Democratic Republic of the Congo (DR Congo), Gabon and the Republic of Congo also have mass vaccination campaigns planned for July.

PATH: New tools for polio surveillance could aid eradication efforts

PATH: New tools for polio surveillance could aid eradication efforts
July 22, 2014
Excerpt
With grant funding made possible by the Paul G. Allen Family Foundation, two new tools to help detect the poliovirus may soon strengthen global efforts to eradicate the disease. The foundation will invest up to US$5.3 million dollars in support of this goal.

The tools, a system to improve environmental surveillance and a simplified diagnostic test, were developed by PATH, a leading international health organization, and researchers at the University of Washington (UW). They have the potential to help workers identify and stop polio by making it easier to find the virus in sewage and among people. Although polio spreads very quickly and can be devastating, many people will never show symptoms—making early detection and response crucial for controlling the spread of disease.

The grant announcement, made today by PATH and UW, comes at a time of heightened attention to the spread of polio worldwide. In early May, the World Health Organization (WHO) declared it a Public Health Emergency of International Concern, warning that the recent spread of the virus from Pakistan, Syria, and Cameroon to neighboring countries could spark widespread epidemics if leaders do not take action.

The initial $2.4 million of the grant, administered in partnership with the Bill & Melinda Gates Foundation, will allow the PATH/UW team to accelerate development, evaluation, and introduction of the tools in coordination with global polio eradication partners. Additional technical and administrative support will be provided by the Gates Foundation as part of its longstanding support for eradication. PATH and UW will seek additional technical advice from the US Centers for Disease Control and Prevention (CDC) and WHO….

WHO Watch [to 26 July 2014]

WHO Watch [to 26 July 2014]
:: WHO Director-General addresses conference on cervical cancer in Africa
Dr Margaret Chan, Director-General of the World Health Organization
Goodwill message to participants of the 8th Stop cervical, breast and prostate cancer in Africa conference: Moving forward to end cervical cancer by 2030: Universal access to cervical cancer prevention
Windhoek, Namibia , 20 July 2014

:: World Hepatitis Day 2014: Think again
25 July 2014 — On World Hepatitis Day, 28 July, WHO welcomes new progress in tackling one of the world’s most serious diseases. Viral hepatitis – a group of infectious diseases known as hepatitis A, B, C, D, and E – affects millions of people worldwide, causing acute and chronic liver disease and killing close to 1.4 million people every year. WHO and partners urge policy-makers, health workers and the public to “think again” about this silent killer.
Find out more about World Hepatitis Day 2014

GAVI Watch [to 26 July 2014]

GAVI Watch [to 26 July 2014]
http://www.gavialliance.org/library/news/press-releases

24 July 2014
German Government to host crucial GAVI Alliance pledging event under the patronage of Chancellor Angela Merkel
Excerpt
Berlin, 24 July 2014 – The German Government today announced that it will convene the GAVI Alliance replenishment pledging meeting under the patronage of Federal Chancellor Angela Merkel in Berlin on 27th January 2015.
The event will mark the final stage of the Alliance’s replenishment process, in which donors have been asked to commit an additional US$ 7.5 billion to support immunisation programmes in developing countries between 2016 and 2020…

CDC/MMWR Watch [to 26 July 2014]

CDC/MMWR Watch [to 26 July 2014]
http://www.cdc.gov/mmwr/mmwr_wk.html

Safe and effective vaccine that prevents cancer continues to be underutilized
Latest vaccination coverage estimates for adolescents show only small increase for HPV vaccine
July 24, 2014
Excerpt
CDC officials announced today that the number of girls and boys aged 13-17 years receiving human papillomavirus (HPV) vaccine remains unacceptably low despite a slight increase in vaccination coverage since 2012, according to data from CDC′s 2013 National Immunization Survey-Teen (NIS-Teen) published in this week′s Morbidity and Mortality Weekly Report (MMWR).
HPV vaccine prevents various forms of cancer, but HPV vaccine remains underutilized. There is a substantial gap between the number of adolescents receiving tetanus, diphtheria, and pertussis (Tdap) vaccine and the number receiving HPV vaccine. It is estimated that only 57 percent of adolescent girls and 35 percent of adolescent boys received one or more doses of HPV vaccine. However, nearly 86 percent of adolescents had received one dose of Tdap vaccine…

MMWR Weekly – July 25, 2014 / Vol. 63 / No. 29
:: World Hepatitis Day — July 28, 2014
:: Progress Toward Prevention of Transfusion-Transmitted Hepatitis B and Hepatitis C Infection — Sub-Saharan Africa, 2000–2011
:: Human Papillomavirus Vaccination Coverage Among Adolescents, 2007–2013, and Postlicensure Vaccine Safety Monitoring, 2006–2014 — United States
:: National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2013
:: WHO Global Rotavirus Surveillance Network: A Strategic Review of the First 5 Years, 2008–2012

GSK announces EU regulatory submission for malaria vaccine candidate RTS,S

Industry Watch [to 26 July 2014]
Selected media releases and other selected content from industry.

GSK announces EU regulatory submission for malaria vaccine candidate RTS,S
24 July 2014, London UK
Excerpt
GSK announced today that it has submitted a regulatory application to the European Medicines Agency (EMA) for its malaria vaccine candidate, RTS,S.

The submission will follow the Article 58 procedure, which allows the EMA to assess the quality, safety and efficacy of a candidate vaccine, or medicine, manufactured in a European Union (EU) member state, for a disease recognised by the World Health Organization (WHO) as of major public health interest, but intended exclusively for use outside the EU. This assessment is done by the EMA in collaboration with the WHO, and requires products to meet the same standards as vaccines or medicines intended for use in the EU. Eligibility for the application was granted by the CHMP after agreement from WHO that RTS,S met criteria for such an evaluation.

RTS,S is intended exclusively for use against the Plasmodium falciparum malaria parasite, which is most prevalent in sub-Saharan Africa (SSA). Around 90 per cent of estimated deaths from malaria occur in SSA, and 77 per cent of these are in children under the age of 5.
The EMA submission is the first step in the regulatory process toward making the RTS,S vaccine candidate available as an addition to existing tools currently recommended for malaria prevention. An effective vaccine for use alongside other measures such as bednets and anti-malarial medicines would represent a advance in malaria control. To-date there is no licensed vaccine available for the prevention of malaria.

If a positive opinion from the EMA is granted, the WHO has indicated a policy recommendation may be possible by end of 2015. A policy recommendation is a formal review process by WHO designed to assist in the development of optimal immunisation schedules for diseases that have a global public health impact, such as malaria…
…Dr Sophie Biernaux, Head of the Malaria Vaccine Franchise, GSK said: “This is a key moment in GSK’s 30-year journey to develop RTS,S and brings us a step closer to making available the world’s first vaccine that can help protect children in Africa from malaria.”….

About RTS,S
:: RTS,S is the scientific name given to this malaria vaccine candidate and reflects the composition of this vaccine candidate that also contains the AS01 adjuvant system[ii].
:: RTS,S aims to trigger the body’s immune system to defend against the P falciparum malaria parasite when it first enters the human host’s bloodstream and/or when the parasite infects liver cells.
:: GSK has taken the lead in the overall development of RTS,S and has invested more than $350 million to date and expects to invest a further $260 million until development is completed. With more than US$200 million in grant monies from the Bill & Melinda Gates Foundation, the PATH Malaria Vaccine Initiative (MVI) contributes financial, scientific, managerial, and field expertise to the development of RTS,S.
:: GSK has committed that the eventual price of RTS,S will cover the cost of manufacturing the vaccine together with a small return of around 5 per cent that will be reinvested in research and development for second-generation malaria vaccines, or vaccines against other neglected tropical diseases.

Report: The Gap – Notes on the IS Global Think Tank on Inequity and Global Health

Report: The Gap – Notes on the IS Global Think Tank on Inequity and Global Health
Barcelona Institute of Global Health
8 July 2014 24 pages
Excerpts
…This paper is ISGlobal’s first attempt to define a position and a work agenda for inequity and global health. In it we outline our reflections on the subject, the questions we are asking ourselves, and the direction of our programme of work in this area. The paper is in part based on the content of the seminar Building a Global Health Social Contract for the 21st Century held in Barcelona in November 2013…
…In the coming months, the world will witness an intense debate about inequity and the best strategy for combating poverty after 2015. The right of millions of people to basic health care is one of the keystones of this debate….

Human papillomavirus infection in Bhutan at the moment of implementation of a national HPV vaccination programme

BMC Infectious Diseases
(Accessed 26 July 2014)
http://www.biomedcentral.com/bmcinfectdis/content

Research article
Human papillomavirus infection in Bhutan at the moment of implementation of a national HPV vaccination programme
Ugyen Tshomo, Silvia Franceschi, Dorji Dorji, Iacopo Baussano, Vanessa Tenet, Peter JF Snijders, Chris JLM Meijer, Maaike CG Bleeker, Tarik Gheit, Massimo Tommasino and Gary M Clifford
Author Affiliations
BMC Infectious Diseases 2014, 14:408 doi:10.1186/1471-2334-14-408
Published: 22 July 2014
Abstract (provisional)
Background
Cervical cancer is the most common female cancer in Bhutan, the first low/middle-income country to implement a national human papillomavirus (HPV) vaccination programme.
Methods
To provide a robust baseline for future evaluations of vaccine effectiveness, cervical cell specimens were obtained from 2,505 women aged 18-69 years from the general population, and biopsies from 211 cervical intraepithelial neoplasia grade 3 (CIN3) and 112 invasive cervical cancer (ICC) cases. Samples were tested for HPV using GP5+/6+ PCR.
Results
Among the general population, HPV prevalence was 26%, being highest (33%) in women <=24 years, but remaining above 15% in all age-groups. Determinants of HPV included age, marital status, and number of sexual partners. Among the eight percent with cytological abnormalities, 24 CIN3 and 4 ICC were histologically confirmed. Even after additional testing with a sensitive E7 PCR, no infections with vaccine-targeted HPV types were detected in the few vaccinated women (n = 34) compared to 6% prevalence in unvaccinated women of similar age (p = 0 . 215).
Conclusion
Based upon type-specific prevalence among biopsies, at least 70% of ICC in Bhutan are theoretically preventable by HPV16/18 vaccination, but screening programmes should be expanded among older women, who have an important underlying burden of CIN3 and ICC.

The niche reduction approach: an opportunity for optimal control of infectious diseases in low-income countries?

BMC Public Health
(Accessed 26 July 2014)
http://www.biomedcentral.com/bmcpublichealth/content

Debate
The niche reduction approach: an opportunity for optimal control of infectious diseases in low-income countries?
Benjamin Roche, Hélène Broutin, Marc Choisy, Sylvain Godreuil, Guillaume Constantin de Magny, Yann Chevaleyre, Jean-Daniel Zucker, Romulus Breban, Bernard Cazelles and Frédéric Simard
Author Affiliations
BMC Public Health 2014, 14:753 doi:10.1186/1471-2458-14-753
Published: 25 July 2014
Abstract (provisional)
Background
During the last century, WHO led public health interventions that resulted in spectacular achievements such as the worldwide eradication of smallpox and the elimination of malaria from the Western world. However, besides major successes achieved worldwide in infectious diseases control, most elimination/control programs remain frustrating in many tropical countries where specific biological and socio-economical features prevented implementation of disease control over broad spatial and temporal scales. Emblematic examples include malaria, yellow fever, measles and HIV. There is consequently an urgent need to develop affordable and sustainable disease control strategies that can target the core of infectious diseases transmission in highly endemic areas.
Discussion
Meanwhile, although most pathogens appear so difficult to eradicate, it is surprising to realize that human activities are major drivers of the current high rate of extinction among upper organisms through alteration of their ecology and evolution, i.e., their “niche”. During the last decades, the accumulation of ecological and evolutionary studies focused on infectious diseases has shown that the niche of a pathogen holds more dimensions than just the immune system targeted by vaccination and treatment. Indeed, it is situated at various intra- and inter- host levels involved on very different spatial and temporal scales. After developing a precise definition of the niche of a pathogen, we detail how major advances in the field of ecology and evolutionary biology of infectious diseases can enlighten the planning and implementation of infectious diseases control in tropical countries with challenging economic constraints.
Summary
We develop how the approach could translate into applied cases, explore its expected benefits and constraints, and we conclude on the necessity of such approach for pathogen control in low-income countries.

Influenza immunization in Canada’s low-income population

BMC Public Health
(Accessed 26 July 2014)
http://www.biomedcentral.com/bmcpublichealth/content

Research article
Influenza immunization in Canada’s low-income population
Jennifer Leigh Hobbs and Jane A Buxton
Author Affiliations
BMC Public Health 2014, 14:740 doi:10.1186/1471-2458-14-740
Published: 21 July 2014
Abstract (provisional)
Background
Immunization offers the best protection from influenza infection. Little evidence describes disparities in immunization uptake among low-income individuals. Higher rates of chronic disease put this population at increased risk of influenza-related complications. This analysis examines if the type of main source of household income in low-income groups affects influenza immunization uptake. We hypothesized that individuals on social assistance have less access to immunization compared to those with employment earnings or seniors’ benefits.
Methods
Data was obtained from the Canadian Community Health Survey annual component 2009-2010. A total of 10,373 low-income respondents (<20,000$ Canadian per annum) were included. Logistic regression, stratified according to type of provincial publicly funded immunization program, was used to examine the association between influenza immunization (in the last 12 months) and main source of household income (employment earnings; social assistance as a combination of employment insurance or worker’s compensation or welfare; or seniors’ benefits).
Results
Overall, 32.5% of respondents reported receiving influenza immunization. In multivariable analysis of universal publicly funded influenza immunization programs, those reporting social assistance (AOR 1.24, 95% CI 1.02-1.51) or seniors’ benefits (AOR 1.56, 95% CI 1.23-1.98) were more likely to be immunized compared to those reporting employment earnings. Similar results were observed for high-risk programs.
Conclusions
Among the low-income sample, overall influenza immunization coverage is low. Those receiving social assistance or seniors’ benefits may have been targeted due to higher rates of chronic disease. Programs reaching the workforce may be important to attain broader coverage. However, CCHS data was collected during the H1N1 pandemic influenza, thus results may not be generalizable to influenza immunization in non-pandemic years.

Editorial Commentary: School-Located Influenza Vaccination: Why Worth the Effort?

Clinical Infectious Diseases (CID)
Volume 59 Issue 3 August 1, 2014
http://cid.oxfordjournals.org/content/current

Editorial Commentary: School-Located Influenza Vaccination: Why Worth the Effort?
Manjusha J. Gaglani1,2
Author Affiliations
1Scott & White Memorial Hospital and Clinic
2Pediatric Infectious Diseases, Texas A&M Health Science Center, Temple
Extract
Influenza viruses cause annual wintertime toll of morbidity and mortality in both hemispheres. The burden of influenza is not evenly borne by everyone; the highest rates of infection are in schoolchildren, and the highest rates of hospitalization and death are in the elderly aged ≥65 years [1]. Influenza vaccines are safe but are only moderately effective in preventing medically attended real-time polymerase chain reaction (RT-PCR)-confirmed influenza. Vaccine effectiveness can be diminished by virus mismatch, increased exposure in crowded environments and immunosenescence with advancing age. Despite maintaining the highest immunization uptake of approximately 65%, effectiveness can be marginal in the elderly, with highest morbidity and mortality seen during seasons when A(H3N2) viruses are predominant.
Daycares and schools provide the ideal environment for spreading influenza, and increased school absences are early indicators of community outbreaks; hospitalizations and deaths increase after the peak activity. After gradually expanding the recommendations to immunize children ages 6–23 months with high hospitalization rates, then children 2–5 years with high outpatient-visit rates, the Centers for Disease Control and Prevention Advisory Committee for Immunization Practices (CDC ACIP) recommended children 5–17 years receive annual influenza immunization beginning 2008–2009 [1]. These were further expanded to include people ages 18–49 years after the 2009 A (H1N1) pandemic so that universal annual influenza vaccines for persons ages ≥6 months is now recommended.
School-located influenza vaccination (SLIV) offers the best option for achieving high-immunization coverage in a short period of time. With SLIV, immunization of approximately 50% (25%–75%) schoolchildren is possible, the highest proportions being elementary schoolchildren. With clinic-based vaccination, uptake of trivalent inactivated influenza vaccine (IIV-3) has generally been higher than …

School-Located Influenza Vaccination Decreases Laboratory-Confirmed Influenza and Improves School Attendance

Clinical Infectious Diseases (CID)
Volume 59 Issue 3 August 1, 2014
http://cid.oxfordjournals.org/content/current

School-Located Influenza Vaccination Decreases Laboratory-Confirmed Influenza and Improves School Attendance
Pia S. Pannaraj1,2, Hai-Lin Wang1, Hector Rivas3, Hilda Wiryawan1, Michael Smit1, Nicole Green3, Grace M. Aldrovandi1,2, Alvin Nelson El Amin4, and Laurene Mascola5
Author Affiliations
1Division of Infectious Diseases, Children’s Hospital Los Angeles
2Department of Pediatrics and Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California
3Public Health Laboratory
4Immunization Program
5Acute Communicable Disease Control, Los Angeles County Department of Public Health,
Abstract
Background.  School-located influenza vaccination (SLV) programs can efficiently immunize large numbers of school-aged children. We evaluated the impact of SLV on laboratory-confirmed influenza and absenteeism.
Methods. Active surveillance for influenza-like illness (ILI) was conducted on 4455 children in 4 SLV intervention and 4 control elementary schools (grades K–6) matched for sociodemographic characteristics during the 2010–2011 influenza season in Los Angeles County, California. Combined nose/throat swabs were collected from febrile children with ILI at presentation to the school nurse or during absenteeism.
Results. In SLV schools, 26.9%–46.6% of enrolled students received at least 1 dose of either inactivated or live attenuated influenza vaccine compared with 0.8%–4.3% in control schools. Polymerase chain reaction for respiratory viruses (PCR) was performed on 1021 specimens obtained from 898 children. Specimens were positive for influenza in 217 (21.3%), including 2009 H1N1 (30.9%), H3 (9.2%), and B (59.9%). Children attending SLV schools, regardless of vaccination status, were 30.8% (95% confidence interval, 10.1%–46.8%) less likely to acquire influenza compared with children at control schools. Unvaccinated children were indirectly protected in the school with nearly 50% vaccination coverage compared with control schools (influenza rate, 27.1 vs 60.0 per 1000 children; P = .023). Unvaccinated children missed more school days than vaccinated children (4.3 vs 2.8 days per 100 school days; P < .001).
Conclusions.  Vaccination of at least a quarter of the school population resulted in decreased influenza rates and improved school attendance. Herd immunity for unvaccinated children may occur in schools with vaccination coverage approaching 50%.

Making use of equity sensitive QALYs: a case study on identifying the worse off across diseases

Cost Effectiveness and Resource Allocation
(Accessed 26 July 2014)
http://www.resource-allocation.com/

Methodology
Making use of equity sensitive QALYs: a case study on identifying the worse off across diseases
Frode Lindemark, Ole Frithjof Norheim and Kjell Arne Johansson
Author Affiliations
Cost Effectiveness and Resource Allocation 2014, 12:16 doi:10.1186/1478-7547-12-16
Published: 23 July 2014
Abstract (provisional)
Background
Resource allocation decisions currently lack standard quantitative methods for incorporating concerns about the worse off when analysing the cost-effectiveness of medical interventions.
Objective
To explore and demonstrate how to identify who are the worse off without a new intervention by measuring lifetime Quality-Adjusted Life Years (QALYs) for patients across different conditions, and compare the results to using proportional shortfall of QALYs.
Methods
Case study of eight condition-intervention pairs that are relevant to priority setting in Norway; childhood deafness (unilateral cochlear implant), unruptured cerebral aneurysm (coiling), morbid obesity (RY gastric bypass), adult deafness (unilateral cochlear implant), atrial fibrillation (catheter ablation), hip osteoarthritis (hip replacement), rheumatoid arthritis (TNF inhibitor) and acute stroke (stroke unit). We extracted prospective QALYs without and with new interventions from published health technology assessments and economic evaluations.
Results
Among the eight cases, the lifetime QALY method and the proportional shortfall method yielded conflicting worse-off rank orders. Particularly two conditions had a substantial shift in ranking across the applications of the two methods: childhood deafness and acute stroke. Deaf children had the lowest expected lifetime QALYs (38.5 without a cochlear implant) and were worst off according to the lifetime approach, while patients with acute stroke had the second-highest lifetime QALYs (76.4 without stroke units). According to proportional shortfall of QALYs, patients with acute stroke were ranked as worse off than deaf children, which seems counterintuitive.
Conclusion
This study shows that it is feasible to identify who are the worse off empirically by the application of lifetime QALYs and proportional shortfalls. These methods ease further examination of whether there is a true conflict between maximization and equity or whether these two concerns actually coincide in real world cases. It is yet to be solved whether proportional prospective health losses are more important than absolute shortfalls in expected lifetime health in judgements about who are worse off.

From global to local: vector-borne disease in an interconnected world

The European Journal of Public Health
Volume 24 Issue 4 August 2014
http://eurpub.oxfordjournals.org/content/current

From global to local: vector-borne disease in an interconnected world
Jonathan E. Suk1 and Jan C. Semenza2
Author Affiliations
1 Country Preparedness Support Section, Public Health Capacity and Communication Unit, European Centre for Disease Prevention and Control, SE-171 83 Stockholm, Sweden
2 Office of the Chief Scientist, European Centre for Disease Prevention and Control, SE-171 83 Stockholm, Sweden
Extract
World Health Day 2014 focused on vector-borne diseases, offering the opportunity to take stock of the remarkable persistence that diseases transmitted by ticks, mosquitoes and other arthropods have exhibited in recent years. It may be tempting to view vector-borne diseases as less of an issue for Europe than other regions of the world, but this would be a mistake. Over the past decade, continental Europe has been subject to local (autochthonous) transmission of the tropical diseases chikungunya and dengue, a Greek outbreak of malaria, significant outbreaks of West Nile virus and the continued geographic expansion of vectors such as the tick species Ixodes ricinus and the mosquito species Aedes albopictus.1
It is both important and revealing to interrogate the myriad factors driving vector-borne disease, particularly those factors that are not considered to be traditionally within the health sector. The risk of transmission can be seen as a function of interrelated and interdependent drivers that can interact on a global scale but manifest themselves locally…

Communicable disease control in Afghanistan

Global Public Health
Volume 9, Supplement 1, 2014
http://www.tandfonline.com/toc/rgph20/.Uq0DgeKy-F9#.U4onnCjDU1w
Special Issue: Afghanistan’s health system: Moving forward in challenging circumstances 2002-2013
Communicable disease control in Afghanistan
Mohammad S. Ikram, Clydette L. Powell, Rashida A. Bano, Arshad D. Quddus, Syad K. Shah, Ellyn L. Ogden, Waqar R. Butt & Mohd Arshil Moideen
pages S43-S57
DOI:10.1080/17441692.2013.826708
Abstract
Among public health challenges in Afghanistan, communicable diseases still predominate because the epidemiologic transition to chronic disease has not yet occurred. Afghanistan’s 10-year journey to improve its response to communicable disease is reflected in varying degrees of progress and innovation, all while long-standing conflict and geographic inaccessibility limit outreach and effective service delivery to vulnerable populations. Although Afghanistan is close to achieving polio elimination, other reportable communicable diseases are only slowly achieving their goals and objectives through targeted, sustained programmatic efforts. The introduction of disease early warning systems has allowed for identification and investigation of outbreaks within 48 hours. Tuberculosis case detection has risen over the last 10 years, and treatment success rates have been sustained at World Health Organization targets over the last 5 years at 85%. These successes are in large part due to increased government commitment, Global Fund support, training of community health workers and improved laboratory capabilities. Malaria cases dropped between 2002 and 2010. HIV/AIDS has been kept at low levels except in only certain sub-sectors of the population. In order to build on these achievements, Afghanistan will need a comprehensive strategy for all communicable diseases, with better human and infrastructure development, better multi-sectoral development and international collaboration.

Can available interventions end preventable deaths in mothers, newborn babies, and stillbirths, and at what cost?

The Lancet
Jul 26, 2014 Volume 384 Number 9940 p281 – 376
http://www.thelancet.com/journals/lancet/issue/current

Series: Every Newborn
Can available interventions end preventable deaths in mothers, newborn babies, and stillbirths, and at what cost?
Prof Zulfiqar A Bhutta PhD a b, Jai K Das MBA b, Rajiv Bahl PhD c, Joy E Lawn PhD d e f, Rehana A Salam MSc b, Vinod K Paul MD g, M Jeeva Sankar DM g, Hannah Blencowe PhD d, Arjumand Rizvi MSc b, Victoria B Chou PhD h, Neff Walker PhD h, for The Lancet Newborn Interventions Review Group, The Lancet Every Newborn Study Group
Summary
Progress in newborn survival has been slow, and even more so for reductions in stillbirths. To meet Every Newborn targets of ten or fewer neonatal deaths and ten or fewer stillbirths per 1000 births in every country by 2035 will necessitate accelerated scale-up of the most effective care targeting major causes of newborn deaths. We have systematically reviewed interventions across the continuum of care and various delivery platforms, and then modelled the effect and cost of scale-up in the 75 high-burden Countdown countries. Closure of the quality gap through the provision of effective care for all women and newborn babies delivering in facilities could prevent an estimated 113 000 maternal deaths, 531 000 stillbirths, and 1•325 million neonatal deaths annually by 2020 at an estimated running cost of US$4•5 billion per year (US$0•9 per person). Increased coverage and quality of preconception, antenatal, intrapartum, and postnatal interventions by 2025 could avert 71% of neonatal deaths (1•9 million [range 1•6—2•1 million]), 33% of stillbirths (0•82 million [0•60—0•93 million]), and 54% of maternal deaths (0•16 million [0•14—0•17 million]) per year. These reductions can be achieved at an annual incremental running cost of US$5•65 billion (US$1•15 per person), which amounts to US$1928 for each life saved, including stillbirths, neonatal, and maternal deaths. Most (82%) of this effect is attributable to facility-based care which, although more expensive than community-based strategies, improves the likelihood of survival. Most of the running costs are also for facility-based care (US$3•66 billion or 64%), even without the cost of new hospitals and country-specific capital inputs being factored in. The maximum effect on neonatal deaths is through interventions delivered during labour and birth, including for obstetric complications (41%), followed by care of small and ill newborn babies (30%). To meet the unmet need for family planning with modern contraceptives would be synergistic, and would contribute to around a halving of births and therefore deaths. Our analysis also indicates that available interventions can reduce the three most common cause of neonatal mortality—preterm, intrapartum, and infection-related deaths—by 58%, 79%, and 84%, respectively.

Rwanda 20 years on: investing in life

The Lancet
Jul 26, 2014 Volume 384 Number 9940 p281 – 376
http://www.thelancet.com/journals/lancet/issue/current

Public Health
Rwanda 20 years on: investing in life
Agnes Binagwaho, Paul E Farmer, Sabin Nsanzimana, Corine Karema, Michel Gasana, Jean de Dieu Ngirabega, Fidele Ngabo, Claire M Wagner, Cameron T Nutt, Thierry Nyatanyi, Maurice Gatera, Yvonne Kayiteshonga, Cathy Mugeni, Placidie Mugwaneza, Joseph Shema, Parfait Uwaliraye, Erick Gaju, Marie Aimee Muhimpundu, Theophile Dushime, Florent Senyana, Jean Baptiste Mazarati, Celsa Muzayire Gaju, Lisine Tuyisenge, Vincent Mutabazi, Patrick Kyamanywa, Vincent Rusanganwa, Jean Pierre Nyemazi, Agathe Umutoni, Ida Kankindi, Christian Ntizimira, Hinda Ruton, Nathan Mugume, Denis Nkunda, Espérance Ndenga, Joel M Mubiligi, Jean Baptiste Kakoma, Etienne Karita, Claude Sekabaraga, Emmanuel Rusingiza, Michael L Rich, Joia S Mukherjee, Joseph Rhatigan, Corrado Cancedda, Didi Bertrand-Farmer, Gene Bukhman, Sara N Stulac, Neo M Tapela, Cassia van der Hoof Holstein, Lawrence N Shulman, Antoinette Habinshuti, Matthew H Bonds, Michael S Wilkes, Chunling Lu, Mary C Smith-Fawzi, JaBaris D Swain, Michael P Murphy, Alan Ricks, Vanessa B Kerry, Barbara P Bush, Richard W Siegler, Cori S Stern, Anne Sliney, Tej Nuthulaganti, Injonge Karangwa, Elisabetta Pegurri, Ophelia Dahl, Peter C Drobac
Preview
Two decades ago, the genocide against the Tutsis in Rwanda led to the deaths of 1 million people, and the displacement of millions more. Injury and trauma were followed by the effects of a devastated health system and economy. In the years that followed, a new course set by a new government set into motion equity-oriented national policies focusing on social cohesion and people-centred development. Premature mortality rates have fallen precipitously in recent years, and life expectancy has doubled since the mid-1990s.

The Lancet Global Health – Aug 2014

The Lancet Global Health
Aug 2014 Volume 2 Number 8 e431 – 487
http://www.thelancet.com/journals/langlo/issue/current

Editorial
Moving the needle on neonatal and child health
Zoë Mullan
Preview
Babies and children feature heavily in this August issue of The Lancet Global Health, as well they should at a time when unfinished agendas are top of the agenda. In its 2014 report on the Millennium Development Goals, released on July 7, the UN described the under-5 mortality goal as “slipping away from achievement by 2015”. The research and opinion in this month’s issue harnesses a variety of different angles from which to “move the needle” on neonatal and child health. How can we ensure that neonatal interventions reach the very poorest families who need them the most? Are we doing enough for children with tuberculosis? What is the role of malaria in low birthweight? And are there any unintended adverse consequences of the introduction of new vaccines in Africa?

Burden of childhood tuberculosis in 22 high-burden countries: a mathematical modelling study
Peter J Dodd, Elizabeth Gardiner, Renia Coghlan, James A Seddon

Estimated risk of placental infection and low birthweight attributable to Plasmodium falciparum malaria in Africa in 2010: a modelling study
Patrick G T Walker, Feiko O ter Kuile, Tini Garske, Clara Menendez, Azra C Ghani

Effects of health-system strengthening on under-5, infant, and neonatal mortality: 11-year provincial-level time-series analyses in Mozambique
Quinhas F Fernandes, Bradley H Wagenaar, Laura Anselmi, James Pfeiffer, Stephen Gloyd, Kenneth Sherr

Effects of the introduction of new vaccines in Guinea-Bissau on vaccine coverage, vaccine timeliness, and child survival: an observational study

The Lancet Global Health
Aug 2014 Volume 2 Number 8 e431 – 487
http://www.thelancet.com/journals/langlo/issue/current

Effects of the introduction of new vaccines in Guinea-Bissau on vaccine coverage, vaccine timeliness, and child survival: an observational study
Dr Ane B Fisker PhD a b, Linda Hornshøj MD a, Amabelia Rodrigues PhD a, Ibraima Balde BSc a, Manuel Fernandes a, Prof Christine S Benn DMSc a b, Prof Peter Aaby DMSc a b
Summary
Background
In 2008, the GAVI Alliance funded the introduction of new vaccines (including pentavalent diphtheria-tetanus-pertussis [DTP] plus hepatitis B and Haemophilus influenzae type b antigens) in Guinea-Bissau. The introduction was accompanied by increased vaccination outreach services and a more restrictive wastage policy, including only vaccinating children younger than 12 months. We assessed coverage of all vaccines in the Expanded Program on Immunizations before and after the new vaccines’ introduction, and the implications on child survival.
Methods
This observational cohort study used data from the Bandim Health Project, which has monitored vaccination status and mortality in randomly selected village clusters in Guinea-Bissau since 1990. We assessed the change in vaccination coverage using cohort data from children born in 2007 and 2009; analysed the proportion of children who received measles vaccine after 12 months of age using data from 1999—2006; and compared child mortality after age 12 months in children who had received measles vaccine and those who had not using data from 1999 to 2006.
Findings
The proportion of children who were fully vaccinated by 12 months of age was 53% (468 of 878) in the 2007 cohort and 53% (467 of 879) in the 2009 cohort (relative risk [RR] 1•00, 95% CI 0•89—1•11). Coverage of DTP-3 and pentavalent-3 increased from 73% (644 of 878) in 2007 to 81% (712 of 879) in 2009 (RR 1•10, 95% CI 1•04 −1•17); by contrast, the coverage of measles vaccination declined from 71% (620 of 878) to 66% (577 of 879; RR 0•93, 0•85—1•01). The effect of the changes was significantly different for DTP-3 coverage compared with measles vaccine coverage (p=0•002). After 12 months of age, the adjusted mortality rate ratio was 0•71 (95% CI 0•56—0•90) for children who had received measles vaccine compared with those who had not (0•59 [0•43—0•80] for girls and 0•87 [0•62—1•23] for boys).
Interpretation
The introduction of the new vaccination programme in 2008 was associated with increased coverage of DTP, but decreased coverage of measles vaccine. In 1999—2006, child mortality was higher in children who had not received measles vaccine than in those who had.
Funding
DANIDA, European Research Council, the Danish Independent Research Council, European Union FP7 via OPTIMUNISE, and Danish National Research Foundation.

Acceptance of Vaccinations in Pandemic Outbreaks: A Discrete Choice Experiment

PLoS One
[Accessed 26 July 2014]
http://www.plosone.org/

Research Article
Acceptance of Vaccinations in Pandemic Outbreaks: A Discrete Choice Experiment
Domino Determann, Ida J. Korfage, Mattijs S. Lambooij, Michiel Bliemer, Jan Hendrik Richardus,
Ewout W. Steyerberg, Esther W. de Bekker-Grob
Published: July 24, 2014
DOI: 10.1371/journal.pone.0102505
Abstract
Background
Preventive measures are essential to limit the spread of new viruses; their uptake is key to their success. However, the vaccination uptake in pandemic outbreaks is often low. We aim to elicit how disease and vaccination characteristics determine preferences of the general public for new pandemic vaccinations.
Methods
In an internet-based discrete choice experiment (DCE) a representative sample of 536 participants (49% participation rate) from the Dutch population was asked for their preference for vaccination programs in hypothetical communicable disease outbreaks. We used scenarios based on two disease characteristics (susceptibility to and severity of the disease) and five vaccination program characteristics (effectiveness, safety, advice regarding vaccination, media attention, and out-of-pocket costs). The DCE design was based on a literature review, expert interviews and focus group discussions. A panel latent class logit model was used to estimate which trade-offs individuals were willing to make.
Results
All above mentioned characteristics proved to influence respondents’ preferences for vaccination. Preference heterogeneity was substantial. Females who stated that they were never in favor of vaccination made different trade-offs than males who stated that they were (possibly) willing to get vaccinated. As expected, respondents preferred and were willing to pay more for more effective vaccines, especially if the outbreak was more serious (€6–€39 for a 10% more effective vaccine). Changes in effectiveness, out-of-pocket costs and in the body that advises the vaccine all substantially influenced the predicted uptake.
Conclusions
We conclude that various disease and vaccination program characteristics influence respondents’ preferences for pandemic vaccination programs. Agencies responsible for preventive measures during pandemics can use the knowledge that out-of-pocket costs and the way advice is given affect vaccination uptake to improve their plans for future pandemic outbreaks. The preference heterogeneity shows that information regarding vaccination needs to be targeted differently depending on gender and willingness to get vaccinated.

The Global Burden of Disease Study 2010: Interpretation and Implications for the Neglected Tropical Diseases

PLoS Neglected Tropical Diseases
(Accessed 26 July 2014)
http://www.plosntds.org/

The Global Burden of Disease Study 2010: Interpretation and Implications for the Neglected Tropical Diseases
Peter J. Hotez, Miriam Alvarado, María-Gloria Basáñez, Ian Bolliger, Rupert Bourne, Michel Boussinesq, Simon J. Brooker, Ami Shah Brown, Geoffrey Buckle, Christine M. Budke, Hélène Carabin, Luc E. Coffeng, Eric M. Fèvre, [ … ], Mohsen Naghavi
Published: July 24, 2014
DOI: 10.1371/journal.pntd.0002865
Introduction
Excerpt
The publication of the Global Burden of Disease Study 2010 (GBD 2010) and the accompanying collection of Lancet articles in December 2012 provided the most comprehensive attempt to quantify the burden of almost 300 diseases, injuries, and risk factors, including neglected tropical diseases (NTDs) [1]–[3]. The disability-adjusted life year (DALY), the metric used in the GBD 2010, is a tool which may be used to assess and compare the relative impact of a number of diseases locally and globally [4]–[6]. Table 1 lists the major NTDs as defined by the World Health Organization (WHO) [7] and their estimated DALYs [1]. With a few exceptions, most of the NTDs currently listed by the WHO [7] or those on the expanded list from PLOS Neglected Tropical Diseases [8] are disablers rather than killers, so the DALY estimates represent one of the few metrics available that could fully embrace the chronic effects of these infections.
Even DALYs, however, do not tell the complete story of the harmful effects from NTDs. Some of the specific and potential shortcomings of GBD 2010 have been highlighted elsewhere [9]. Furthermore, DALYs measure only direct health loss and, for example, do not consider the economic impact of the NTDs that results from detrimental effects on school attendance and child development, agriculture (especially from zoonotic NTDs), and overall economic productivity [10], [11]. Nor do DALYs account for direct costs of treatment, surveillance, and prevention measures. Yet, economic impact has emerged as an essential feature of the NTDs, which may trap people in a cycle of poverty and disease [10]–[12]. Additional aspects not considered by the DALY metrics are the important elements of social stigma for many of the NTDs and the spillover effects to family and community members [13], [14], loss of tourism [15], and health system overload (e.g., during dengue outbreaks). Ultimately NTD control and elimination efforts could produce social and economic benefits not necessarily reflected in the DALY metrics, especially among the most affected poor communities [11]…

Ebola drugs still stuck in lab

Science
25 July 2014 vol 345, issue 6195, pages 353-480
http://www.sciencemag.org/current.dtl
In Depth
Infectious Diseases
Ebola drugs still stuck in lab
Martin Enserink
Summary
With 1048 reported cases and 632 deaths since March, the West African Ebola outbreak shows no signs of tapering off and has even reached several capital cities. Several drugs and vaccines are in development against the virus, some of which have already shown great promise in animals, but have not completed human safety tests. As the outbreak worsened, debates intensified among scientists, government officials, and company executives about bringing some of these unapproved products to Africa on a so-called compassionate use basis. But the organizations fighting Ebola on the ground say they can’t bring an untested, unlicensed drug or vaccine to a population that’s already distrustful of the teams fighting the outbreak.

The most ambitious vaccine introduction in history [IPV]

Vaccine
Volume 32, Issue 36, Pages 4599-4702 (6 August 2014)
http://www.sciencedirect.com/science/journal/0264410X/32/36

The most ambitious vaccine introduction in history [IPV]
Elizabeth Miller
Pages 4599-4601
No abstract; Excerpt from initial text
…The Global Polio Eradication Initiative’s (GPEI) “Polio Eradication and Endgame Strategic Plan 2013–2018” calls for IPV introduction in these countries by the end of 2015. This schedule is unprecedented in its speed and scope, and must be accompanied by concerted action in key countries to strengthen their immunization systems. But if done right, IPV introduction has the potential to be a uniquely rewarding achievement in public health….

Determinants of uptake of influenza vaccination among pregnant women – A systematic review

Vaccine
Volume 32, Issue 36, Pages 4599-4702 (6 August 2014)
http://www.sciencedirect.com/science/journal/0264410X/32/36

Determinants of uptake of influenza vaccination among pregnant women – A systematic review
Review Article
Carol Yuet Sheung Yuen, Marie Tarrant
Pages 4602-4613
Abstract
Background
Pregnant women have the highest priority for seasonal influenza vaccine. However, suboptimal coverage has been repeatedly noted in this population. To improve vaccine uptake, reviewing the determinants of vaccination is of increasing importance.
Methods
A detailed literature search was performed up to November 30, 2013 to retrieve articles related to uptake of influenza vaccination during pregnancy.
Results
Forty-five research papers were included in the review. Twenty-one studies assessed the coverage of seasonal influenza vaccination, 13 studies assessed coverage of A/H1N1 pandemic vaccination and 11 studies assessed both. Vaccination uptake ranged from 1.7% to 88.4% for seasonal influenza, and from 6.2% to 85.7% for A/H1N1 pandemic influenza. Many pregnant women were unaware that they were at high risk for influenza and its complications during pregnancy. They were also more likely to underestimate the threat of influenza to themselves and their fetus. Moreover, they had substantial concerns about the safety and efficacy of the influenza vaccine during pregnancy. Negative media reports contributed to the perception that influenza vaccination during pregnancy was risky and could result in adverse pregnancy outcomes. Although health care providers’ (HCPs) recommendations were consistently associated with vaccine uptake, most did not recommend the vaccine to their pregnant clients.
Conclusions
Influenza vaccination uptake among pregnant women is suboptimal and HCPs rarely recommend it. Positive vaccination recommendations from HCPs as well as direct access to the vaccine would likely substantially improve vaccination acceptance.

Engaging parents and schools improves uptake of the human papillomavirus (HPV) vaccine: Examining the role of the public health nurse

Vaccine
Volume 32, Issue 36, Pages 4599-4702 (6 August 2014)
http://www.sciencedirect.com/science/journal/0264410X/32/36

Engaging parents and schools improves uptake of the human papillomavirus (HPV) vaccine: Examining the role of the public health nurse
Original Research Article
Noella W. Whelan, Audrey Steenbeek, Ruth Martin-Misener, Jeffrey Scott, Bruce Smith, Holly D’Angelo-Scott
Pages 4665-4671
Abstract
Background
Nova Scotia has the highest rate of cervical cancer in Canada, and most of these cases are attributed to the Human Papillomavirus (HPV). In 2007, Gardasil® was approved and implemented in a successful school-based HPV immunization program. Little is known, however, which strategies (if any) used within a school-based program help to improve vaccine uptake.
Methods
A retrospective, exploratory correlation study was conducted to examine the relationship between school-based strategies and uptake of HPV vaccine. Data was analyzed through Logistic regression, using PASW Statistics 17 (formerly SPSS 17).
Results
HPV vaccine initiation was significantly associated with Public Health Nurses providing reminder calls for: consent return (p = 0.017) and missed school clinic (p = 0.004); HPV education to teachers (p < 0.001), and a thank-you note to teachers (p < 0.001). Completion of the HPV series was associated with vaccine consents being returned to the students’ teacher (p = 0.003), and a Public Health Nurse being assigned to a school (p = 0.025).
Conclusions
These findings can be used to help guide school-based immunization programs for optimal uptake of the HPV vaccine among the student population.

Evaluation of the measles, mumps and rubella vaccination catch-up campaign in England in 2013

Vaccine
Volume 32, Issue 36, Pages 4599-4702 (6 August 2014)
http://www.sciencedirect.com/science/journal/0264410X/32/36

Evaluation of the measles, mumps and rubella vaccination catch-up campaign in England in 2013
Original Research Article
Benedetto Simone, Sooria Balasegaram, Maya Gobin, Charlotte Anderson, André Charlett, Louise Coole, Helen Maguire, Tom Nichols, Chas Rawlings, Mary Ramsay, Isabel Oliver
Pages 4681-4688
Abstract
In January–March 2013 in England, confirmed measles cases increased in children aged 10–16 years. In April–September 2013, the National Health System and Public Health England launched a national measles-mumps-rubella (MMR) campaign based on data from Child Health Information Systems (CHIS) estimating that approximately 8% in this age group were unvaccinated. We estimated coverage at baseline, and, of those unvaccinated (target), the proportion vaccinated up to 20/08/2013 (mid-point) to inform further public health action.
We selected a sample of 6644 children aged 10–16 years using multistage sampling from those reported unvaccinated in CHIS at baseline and validated their records against GP records. We adjusted the CHIS MMR vaccine coverage estimates correcting by the proportion of vaccinated children obtained through sample validation.
We validated 5179/6644 (78%) of the sample records. Coverage at baseline was estimated as 94.7% (95% confidence intervals, CI: 93.5–96.0%), lower in London (86.9%, 95%CI: 83.0–90.9%) than outside (96.1%, 95%CI 95.5–96.8%). The campaign reached 10.8% (95%CI: 7.0–14.6%) of the target population, lower in London (7.1%, 95%CI: 4.9–9.3) than in the rest of England (11.4%, 95%CI: 7.0–15.9%). Coverage increased by 0.5% up to 95.3% (95% CI: 94.1–96.4%) but an estimated 210,000 10–16 year old children remained unvaccinated nationally.
Baseline MMR coverage was higher than previously reported and was estimated to have reached the 95% campaign objective at midpoint. Eleven per cent of the target population were vaccinated during the campaign, and may be underestimated, especially in London. No further national campaigns are needed but targeted local vaccination activities should be considered.

Vaccines and Global Health: The Week in Review 19 July 2014

Vaccines and Global Health: The Week in Review is a weekly digest — summarizing news, events, announcements, peer-reviewed articles and research in the global vaccine ethics and policy space. Content is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage. You are viewing the blog version of our weekly digest, typically comprised of between 30 and 40 posts below all dated with the current issue date

.Request an Email Summary: Vaccines and Global health : The Week in Review is published as a single email summary, scheduled for release each Saturday evening before midnight (EDT in the U.S.). If you would like to receive the email version, please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.
.
pdf versionA pdf of the current issues is available here: Vaccines and Global Health_The Week in Review_19 July 2014

Twitter:  Readers can also follow developments on twitter: @vaxethicspolicy.
.
Links:  We endeavor to test each link as we incorporate it into any post, but recognize that some links may become “stale” as publications and websites reorganize content over time. We apologize in advance for any links that may not be operative. We believe the contextual information in a given post should allow retrieval, but please contact us as above for assistance if necessary.
.
Support:  If you would like to join the growing list of individuals who support this service and its contribution to their roles in public health, clinical practice, government, IGOs/NGOs, research, industry and academia, please visit this page at The Wistar Institute, our co-founder and fiduciary. Thank you…
.

.
David R. Curry, MS
Executive Director
Center for Vaccine Ethics and Policy
a program of the
– Division of Medical Ethics, NYU Medical School
– The Wistar Institute Vaccine Center
– Children’s Hospital of Philadelphia Vaccine Education Center
Associate Faculty, Division of Medical Ethics, NYU Medical School

WHO-UNICEF: Immunization coverage reaches 84%, still short of 90% goal

WHO-UNICEF: Immunization coverage reaches 84%, still short of 90% goal
Excerpt from Overview
More than 111 million infants received vaccines in 2013 to protect them from deadly diseases. These infants account for about 84% of the world’s children, but an estimated 21.8 million infants remained unvaccinated, according to new estimates from WHO and UNICEF

The estimates tell a success story for the Expanded Programme on Immunization, namely that global coverage with vaccines, measured by the proportion of kids who received 3 doses of vaccines containing diphtheria tetanus-pertussis (DTP3), rose from 73% in 2000 to 84% in 2013, a substantial increase.

But the numbers still fall short of the goal set out in the Global Vaccine Action Plan, which was endorsed by the World Health Assembly in 2012. That plan, which aims to prevent millions of deaths through more equitable access to vaccines, has a target of 90% coverage for all vaccines by the year 2020. The percentage of children who receive vaccines has been above 80% since 2006.

“We face a challenge in closing the gap between 84% and 90%,” said Michel Zaffran, Coordinator of WHO’s Expanded Programme on Immunization. “The countries have succeeded in maintaining a high level of vaccination coverage while, at the same time, introducing new vaccines and immunizing an increasing number of children born each year. However, it is hard for them to reach all children including those in remote areas or in urban slums.”

Small anti vaccination groups in some countries, Zaffran noted, also sometimes cause difficulties with misinformation about vaccines, presenting added challenges to national immunization programs in some cases.

Three of WHO’s regions reported very high immunization coverage: the Western Pacific with 96%; the European Region with 96%; and the Region of the Americas with 90%. Coverage was slightly lower in the: Eastern Mediterranean Region at 82%; in the South-East Asia Region at 77%; and in the African Region at 75%.

The data used in these estimates comes from official reports by national authorities as well as survey data from the published and grey literature. On a country by country basis, about two thirds of WHO’S 194 Member States achieved immunization coverage of 90% or higher for the commonly used DPT3 vaccine measurement, the figures show.

Global coverage with at least one dose of measles containing vaccine was 84% and 128 WHO member states reached at least 90% national coverage. An estimated 52% of children were vaccinated with 2 doses of measles containing vaccine during 2013 through routine immunization services.
Data on WHO immunization coverage

UN OCHA: Central Emergency Response Fund allocates $1.4 million to fight measles outbreak in Somalia

UN Watch [to 19 July 2014]
:: UN OCHA: Central Emergency Response Fund allocates $1.4 million to fight measles outbreak in Somalia
UN Office for the Coordination of Humanitarian Affairs
Excerpt
Mogadishu, 14 July 2014: The United Nations Central Emergency Response Fund (CERF) has allocated US$1.4 million for an emergency campaign to combat the outbreak of measles in Somalia, that has already left thousands of children at risk of disability and death. The funding will be used to vaccinate 520,000 children under 5 years in the worst affected areas of Banadir, Lower Juba and Puntland.

Around 4,000 suspected cases of measles were reported between January and June, more than double the suspected cases seen in the same period last year. Three quarters of cases were reported in children under 5 years.

“The CERF funding comes at a crucial time when thousands of children’s lives are at risk,” said the Humanitarian Coordinator for Somalia, Philippe Lazzarini, who is responsible for pooled fund allocation at country level. “The vaccination drive will help prevent the spread of the disease to other locations, particularly those inaccessible to vaccination teams. A nationwide catch-up campaign will be conducted in the next six months as part of the overall measles control strategy.”…The CERF allocation will be complemented by $300,000 from the Somalia Common Humanitarian Fund.

The Central Emergency Response Fund is a global pooled humanitarian fund set up in 2005 to enable more timely and reliable humanitarian assistance to people affected by armed conflicts and natural disasters. It is funded by voluntary contributions from UN Member States, NGOs, local government, the private sector and individual donors, and is managed by UNOCHA. The Common Humanitarian Fund is country-based and managed by UNOCHA on behalf of the Humanitarian Coordinator.

POLIO [to 19 July 2014]

POLIO [to 19 July 2014]

GPEI Update: Polio this week – As of 9 July 2014
Global Polio Eradication Initiative
Editor’s Excerpt and text bolding
Full report: http://www.polioeradication.org/Dataandmonitoring/Poliothisweek.aspx
:: Momentous opportunity for Africa: In its 2-3 July meeting, the Central African Technical Advisory Group noted that there is now a “momentous opportunity” for Africa to be polio-free and warned that there is a lack of urgency to capitalize on this opportunity.
:: New case in Afghanistan of Pakistan origin: A child who had onset of polio-paralysis in Khost Province of Afghanistan is a member of the displaced community from Pakistan’s North Waziristan Agency, where children have not had access to vaccination for two years. Ahead of and during military action in that Agency, the population has largely left the area and moved into surrounding areas of Pakistan and into Afghanistan. Massive vaccination operations are taking place at the transit points out of North Waziristan in order to protect Waziri children and the rest of Pakistan from polio.
Afghanistan
:: One new case of wild poliovirus type 1 (WPV1) was reported in the past week, from Khost Province. The child is from a Pakistani family from polio-endemic North Waziristan who fled to Afghanistan to escape conflict at home. Already ill with fever when leaving Pakistan, the child developed paralysis on 16 June, 2014, in Khost province, one day after arrival from N. Waziristan. Including this most recent case, Afghanistan has reported eight polio cases to date in 2014, compared to three at this time in 2013.
:: Khost Province borders Pakistan, where communities displaced by military action have been leaving North Waziristan Agency. In preparation for the displacement of people – and possible movement of the virus – ahead of the Pakistan military’s actions in North Waziristan, health authorities in surrounding districts of Pakistan and across the border in Afghanistan have been vaccinating displaced children: more than 35,000 displaced children under the age of 10 are reported to have received a dose of bivalent oral polio vaccine (bOPV) as they entered the Afghan provinces of Paktyka and Khost.
Nigeria
:: Two new cVDPV2 cases were reported in the past week, from Borno and Kano states. The total number of cVDPV2 cases for 2014 is now 13, and for 2013 is four. The most recent cVDPV2 case was the one from Damboa in Borno, which had onset of paralysis on 9 June. The continuing circulation of cVDPV2, as evident both from AFP and environmental surveillance , reflects very low levels of routine coverage with tOPV (and therefore very low immunity against type 2 poliovirus) in the north of the country and the need for increased use of type-2 containing vaccine (tOPV) during SIAs. It is also urgent that the quality and coverage of SIAs in northern Nigeria continue to improve this year
Pakistan
:: Four new wild poliovirus type 1 (WPV1) cases were reported in the past week, bringing the country’s total case count to 94. The most recent cases had onset of paralysis on 24 June, one from Khyber Agency of the Federally Administered Tribal Areas (FATA), one from Peshawar in Khyber Pakhtunkhwa province and one from Sanghar in Sindh province.
Central Africa
:: In its 2-3 July meeting, the Central African Technical Advisory Group noted that there is now a “momentous opportunity” for Africa to be polio-free, given the decline in cases in Nigeria, and warned that there is a lack of urgency to capitalize on this opportunity. The group recommended systematic engagement with the Heads of State and a region-wide alert on the potential spread of polio to ensure countries reduce their vulnerability and are prepared to deal with importation of poliovirus.
:: The entire population of Equatorial Guinea, regardless of age, will be vaccinated starting 23 July. A house-to-house search for acute flaccid paralysis cases will be conducted during the campaign; a similar search is currently taking place in Gabon. Cameroon, the Central African Republic, the Democratic Republic of the Congo (DR Congo), Gabon and the Republic of Congo also have mass vaccination campaigns planned for July. DR Congo, Equatorial Guinea and Gabon are also planning to carry out campaigns in August.
Horn of Africa
:: Three new cases of wild poliovirus type 1 were reported in the past week. Five cases have been reported in the Horn of Africa to date in 2014 – one WPV1 in Ethiopia and four WPV1 in Somalia. The most recent case had onset of paralysis on 3 June in Mudug, Somalia.
:: The three new cases reported from Mudug in Somalia bring the total no. of cases reported from the Mudug Region (Jariban) this year to four and indicate that the polio outbreak in Somalia continues. The cases are caused by virus closely related to that previously detected in Mogadishu in July 2013. No cases have been detected in the epicentre of the outbreak, in Mogadishu, Banadir region, since 19 July 2013.
:: Mudug is a remote area with challenging conditions to plan and implement immunization campaigns and with hard-to-reach, under-served nomadic populations. While the proportion of children with three or more doses of oral polio vaccine has risen since 2012, it is still below 80%. None of the children paralyzed in Mudug had ever been vaccinated against polio.
Special outreach is currently taking place to reach and vaccinate nomadic communities, as well as to map of these communities to ensure their inclusion in vaccination plans.

Pakistanis use fake polio vaccination cards to travel overseas
Thomson Reuters Foundation | 11 July 2014
Excerpt
NEW DELHI, July 11 (Thomson Reuters Foundation) – Pakistanis seeking to travel overseas have used fake polio vaccination certificates to circumvent rules put in place to stem the spread of the crippling virus, the Dawn newspaper reported.
The World Health Organisation (WHO) in May advised Pakistan, Syria and Cameroon to put in place emergency travel measures as they pose the greatest risk of exporting the virus and undermining a U.N. plan to eradicate polio by 2018.
The WHO recommended that residents and long-term visitors to these three countries be vaccinated and show proof of vaccination before being allowed to travel.
But since the rule was put in place in Pakistan in June, immigration staff at Islamabad’s Benazir Bhutto International Airport told the Dawn newspaper they had found around 150 polio certificates to be counterfeit.
An airport official, who declined to be named, said that some people had obtained fake certificates because they believed the vaccine could endanger their health…

Editor’s Note: Please note “comment” articles on polio from the current issue of Nature in Journal Watch below:
:: Within reach — A redoubling of efforts should swiftly eradicate polio from its last strongholds
Nature editors
:: Infectious disease: Polio eradication hinges on child health in Pakistan
Zulfiqar Ahmed Bhutta

WHO: Global Alert and Response (GAR) – Disease Outbreak News [to 19 July 2014]

WHO: Global Alert and Response (GAR) – Disease Outbreak News [to 19 July 2014]
http://www.who.int/csr/don/en/

:: Update on polio in Equatorial Guinea 17 July 2014
As of 16 July 2014, Equatorial Guinea has reported a total of 5 wild poliovirus type 1 (WPV1) cases, with onset of paralysis between 28 January 2014 (first case) and 3 May 2014 (most recent case). Genetic sequencing indicated that the cases are linked to the ongoing outbreak in Cameroon.
A national emergency action plan to respond to the polio outbreak was developed by the Ministry of Health and polio partner agencies and is being implemented. Three nationwide campaigns with bivalent oral polio vaccine (bOPV) have already been conducted in the country – two campaigns targeting children under 15 years old in April 2014 and early May 2014, and one in late May 2014 targeting children under 5 years old. Two nationwide bOPV campaigns are planned for mid-July 2014 and mid-August 2014; the July 2014 round will target the entire population, and the August 2014 round will target children under 15 years old…
…According to the International Health Regulations (IHR) Temporary Recommendations issued by the Director-General of WHO on 5 May 2014, Equatorial Guinea is considered as a polio exporting country.
The country is therefore working to ensure that all residents and long-term visitors (of more than 4 weeks) who travel internationally receive a supplementary dose of polio vaccine between 4 weeks and 12 months prior to departure

:: Ebola virus disease, West Africa – update 15 July 2014
Epidemiology and surveillance
The World Health Organization (WHO) continues to closely monitor the evolving Ebola virus disease (EVD) outbreak in Guinea, Liberia, and Sierra Leone. The current epidemic trend in Sierra Leone and Liberia remains serious, with high numbers of new cases and deaths being reported. Between 8 – 19 July 2014, 79 new cases, and 65 deaths were reported from Liberia and Sierra. In Liberia, 30 new cases and 13 deaths were reported, while in Sierra Leone, 49 new cases and 52 deaths have been reported. These include suspect, probable and laboratory confirmed cases. This trend indicates that a high level of transmission of the Ebola Virus continues to take place in the community. The epidemic situation in Guinea is being closely observed, with 6 new cases and 3 deaths reported between 8 – 19 July 2014. The respective Ministries of Health are working with WHO and partners to step up outbreak containment measures….

:: Middle East respiratory syndrome coronavirus (MERS-CoV) – update 14 July 2014

Global Fund Watch [to 19 July 2014]

Global Fund Watch [to 19 July 2014]
http://www.theglobalfund.org/en/mediacenter/announcements/
:: Global Fund Results Show Strong Gains
17 July 2014
Excerpt
GENEVA – The Global Fund announced today that 6.6 million people are getting antiretroviral treatment for HIV through programs supported by Global Fund grants, with particularly strong gains in Nigeria, Mozambique, India, and Uganda this year. In mid-year results for 2014, the Global Fund also reported that programs supported by its grants have distributed a total of more than 410 million mosquito nets to protect children and families against malaria, an increase of 14 percent.

In addition, 11.9 million people have been treated for tuberculosis in programs supported by the Global Fund. In the first half of 2014, the number of people treated for multidrug resistant tuberculosis rose to nearly 140,000 from 110,000.

“These results show that we are accelerating progress against HIV, TB and malaria,” said Mark Dybul, Executive Director of the Global Fund. “We can do even more, and reach more people, when we work together and concentrate our efforts on those who are most vulnerable.”

This year, the Global Fund is in a transition in how to assess impact that better reflects the collective contribution towards goals and targets. In that process, the Global Fund is working with partners and experts to arrive at an improved methodology to measure health impact of HIV, TB and malaria programs…

WHO Regionals Watch [to 19 July 2014]

WHO Regionals Watch [to 19 July 2014]
:: Countries of the Americas hold national consultations to make universal health coverage a regional priority
With PAHO support, health authorities are engaging other sectors in dialogues on the best way forward to ensure equitable access to quality care for everyone
Washington, D.C., 16 July 2014 (PAHO/WHO) – The countries of the Americas are holding national consultations to discuss the way forward to reach universal health coverage, with the support of the Pan American Health Organization/World Health Organization (PAHO/WHO).
National health authorities and other health sector actors are participating in the dialogues, which will help shape a regional roadmap for achieving universal health coverage that will be submitted for the approval of the 53rd PAHO Directing Council in September. Consultations have already been held in 27 countries and are scheduled to be held in four others in the coming weeks.
“Universal health coverage is a means to attain health and well-being for all people. It is based on the right of every person to enjoy optimal health, with equity and solidarity, and it is responsibility of all governments,” said PAHO/WHO Director Carissa F. Etienne. “PAHO is supporting national, subregional, and regional consultations that facilitate a broad dialogue so that all the voices of the Americas, including those of the most vulnerable groups, can be heard during this process.”
Universal health coverage means that all people and communities have equitable access to the comprehensive and guaranteed quality services that they need, throughout the course of their lives, without financial hardship…

.

THE GAP REPORT – BEGINNING OF THE END OF THE AIDS EPIDEMIC

THE GAP REPORT – BEGINNING OF THE END OF THE AIDS EPIDEMIC
UNAIDS / JC2656 (English original, July 2014) 422 pages
ISBN 978-92-9253-062-4
How do we close the gap between the people moving forward and the people being left behind? This was the question we set out to answer in the UNAIDS Gap report. Similar to the Global report, the goal of the Gap report is to provide the best possible data, but, in addition, to give information and analysis on the people being left behind.

FDA: Informed Consent Information Sheet – Guidance for IRBs, Clinical Investigators, and Sponsors 1 DRAFT GUIDANCE FOR COMMENT

FDA: Informed Consent Information Sheet – Guidance for IRBs, Clinical Investigators, and Sponsors 1
DRAFT GUIDANCE FOR COMMENT
http://www.fda.gov/RegulatoryInformation/Guidances/ucm404975.htm
07/15/2014:
This draft guidance is intended to assist IRBs, clinical investigators, and sponsors involved in clinical investigations of FDA-regulated products in carrying out their responsibilities related to informed consent. The guidance provides the Agency’s recommendations and requirements for informed consent to assure the protection of the rights and welfare of human subjects in clinical investigations. This guidance describes the basic and additional elements of informed consent and includes topics such as review of patient records, children as subjects, and subject participation in more than one study.
Comments due by September 15, 2014

Influenza Vaccination Among Persons with Work-Related Asthma

American Journal of Preventive Medicine
Volume 47, Issue 2, p105-232, e3-e6 August 2014
http://www.ajpmonline.org/current

Influenza Vaccination Among Persons with Work-Related Asthma
Jacek M. Mazurek, MD, Gretchen E. White, MPH, Jeanne E. Moorman, MS, Eileen Storey, MD
Published Online: June 17, 2014
DOI: http://dx.doi.org/10.1016/j.amepre.2014.04.007
Abstract
Background
Seasonal influenza vaccination is recommended for all asthma patients. Persons with work-related asthma may have more severe disease than those with non–work-related asthma and may particularly benefit from receiving influenza vaccination.
Purpose
To determine if influenza vaccination coverage differs among individuals aged 18–64 years with work-related and non–work-related asthma.
Methods
Data from the 2006–2009 Behavioral Risk Factor Surveillance System Asthma Call-Back Survey collected in 38 states and the District of Columbia were analyzed in 2013. Multivariable logistic regression and predictive marginal analyses were conducted to identify factors independently associated with influenza vaccination among respondents aged 18–64 years with work-related asthma.
Results
Among adults aged 18–64 years with current asthma, an estimated 42.7% received influenza vaccination in the past 12 months. Although influenza vaccination coverage was significantly higher among adults with work-related asthma than those with non–work-related asthma (48.5% vs 42.8%), this association became non-significant after adjustment for demographic and clinical characteristics (prevalence ratio=1.08, 95% CI=0.99, 1.20). Among individuals with work-related asthma, receiving the influenza vaccine was associated with being 50–64 years old, being unemployed in the prior year, and seeking urgent treatment for worsening asthma symptoms.
Conclusions
Among persons with work-related and non–work-related asthma, less than half received influenza vaccination in the prior year, both below the Healthy People 2010 target of 60%. These results suggest the need for strengthening current vaccination interventions to meet the updated Healthy People 2020 objective of achieving at least 70% influenza vaccination coverage.

Responding to Measles in the Postelimination Era

Annals of Internal Medicine
15 July 2014, Vol. 161. No. 2
http://annals.org/issue.aspx

Ideas and Opinions | 15 July 2014
Ready or Not: Responding to Measles in the Postelimination Era
Julia Shaklee Sammons, MD, MSCE
Article and Author Information
Ann Intern Med. 2014;161(2):145-146. doi:10.7326/M14-0892

Although endemic measles was eliminated in the United States in 2000 (1), 2 concurrent measles outbreaks at opposite ends of the country offer a sobering reminder of the threat of this global disease. As more parents decline to vaccinate their children, measles incidence is increasing—a fact that alarms me both as a hospital epidemiologist and as a parent of a vulnerable infant too young to receive the measles vaccine. Because infected patients are likely to seek medical care, hospitals and clinics may inadvertently fuel transmission if patients with measles are not rapidly triaged and isolated. Yet, because of the success of the measles vaccine, many clinicians have never seen measles and may not be able to recognize its features. It is crucial that providers become familiar with this deadly disease and apply the necessary control measures to contain it…
…As measles incidence increases, clinicians have a vital role to play. We need to talk to our patients about measles vaccination and remind them what is at stake if imported measles cases continue to land in communities of unvaccinated persons, especially for those who are too young or ineligible to be vaccinated. Meanwhile, we must ensure that our facilities do not become centers for secondary measles transmission—prompt recognition of suspected cases and rapid implementation of control measures are critical to prevent further spread.

Protecting newborns from pertussis – the challenge of complete cocooning

BMC Infectious Diseases
(Accessed 19 July 2014)
http://www.biomedcentral.com/bmcinfectdis/content

Research article
Protecting newborns from pertussis – the challenge of complete cocooning
Pascal Urwyler and Ulrich Heininger
Author Affiliations
BMC Infectious Diseases 2014, 14:397 doi:10.1186/1471-2334-14-397
Published: 17 July 2014
Abstract (provisional)
Background
An increase of pertussis cases, especially in young infants and adolescents, has been noted in various countries. Whooping cough is most serious in neonates and young infants in whom it may cause serious complications such as cyanosis, apnoea, pneumonia, encephalopathy and death. To protect newborns and infants too young to be fully immunized, immunization of close contact persons has been proposed (“cocoon strategy”) and implemented in several countries, including Switzerland in 2011. The goal of this study was to assess knowledge about pertussis among parents of newborns and acceptance, practicability and implementation of the recently recommended pertussis cocoon strategy in Switzerland.
Methods
We performed a cross sectional survey among all parents of newborns born between May and September 2012 and 2013 in Basel city and country. Regional statistical offices provided family addresses after approval by the ethical and data protection committees. A standardized questionnaire with detailed instructions was sent to all eligible families. For statistical analyses, independent proportions were compared by Pearson’s chi-squared test.
Results
Of 3546 eligible parents, 884 (25%) participated. All three questions exploring pertussis knowledge were answered correctly by 37% of parents; 25% gave two correct answers, 22% gave one correct answer and in the remaining 16% no answer was correct. Pertussis immunization as part of cocooning was recommended to 20% and 37% of mothers and 14% and 32% of fathers in the 2012 and 2013 study cohorts, respectively. Principal advisors for cocooning were pediatricians (66%) followed by gynecologists/obstetricians (12%) and general practitioners (5%). When recommended, 64% of mothers and 59% of fathers accepted pertussis immunization. The majority of vaccinations were administered in the perinatal period and within 2 months of the child’s birth. However, cocooning remained incomplete in 93% of families and in most families <50% of close contacts received pertussis vaccination.
Conclusions
Implementation of cocooning for protecting newborns from pertussis is challenging and usually remains incomplete. Pertussis immunization rates among close contacts of newborns need to be improved. Ideally, all healthcare providers involved in family planning, pregnancy and child birth should recommend cocooning. Pertussis immunization of pregnant women is an additional measure for optimal protection of newborns and should be promoted.

Editorial: Preventing pertussis

British Medical Journal
19 July 2014(vol 349, issue 7967)
http://www.bmj.com/content/349/7967

Editorials
Preventing pertussis
We need to act now, not wait for longer lasting new vaccines
Pertussis (whooping cough) continues to be a major cause of morbidity and mortality throughout the world and is one of the leading causes of deaths from vaccine preventable diseases. In recent years, large outbreaks of pertussis have been reported in many developed countries, despite widespread use of vaccines.1 2…

…There is uncertainty about the causes of the apparent resurgence of pertussis. Possible contributors include more sensitive and more readily available methods for diagnosis; enhanced awareness and more complete reporting; decreased duration of adaptive immunity after immunization with acellular vaccines (compared with whole cell vaccines), perhaps related to a decreased T helper type 1 immune response; and mismatch between the antigens in the acellular vaccines and those of circulating strains of B pertussis. Although the largest increase in reported incidence seems to be in adolescents, children aged <3 months are at highest risk of serious morbidity and mortality from pertussis.

Immunity to pertussis, whether vaccine induced or from natural infection, is not life long. So there is a large pool of susceptible adults and adolescents to serve as a reservoir for pertussis in the community. There is now substantial evidence, however, that immunity induced by acellular pertussis vaccines, which in many countries have replaced the more reactogenic whole cell vaccines, wanes most rapidly.6…

…Modifications of current vaccines might also help in the near term. If formulations of acellular pertussis vaccines were available without other components, such as diphtheria toxoid or inactivated polio vaccine, it might encourage recommendations for more frequent booster doses of pertussis vaccine to reduce the pool of susceptible persons. Improving the immune response by adding extra antigens of B pertussis to existing vaccines, changing adjuvants, or adding new ones could be another short term solution.

However, there is general agreement that new and more durable vaccines are needed.12 Unfortunately, development and licensure of such new products require a substantial investment of money and time. Examples of such longer term solutions include new live attenuated vaccines that could be administered intranasally or perhaps a genetically engineered vaccine that uses bacteria, viruses, or other vehicles to deliver bacterial antigens. It is clear that we need redoubled efforts to combat the real, persistent, and potentially lethal threat of pertussis.

Whooping cough in school age children presenting with persistent cough in UK primary care after introduction of the preschool pertussis booster vaccination: prospective cohort study
BMJ 2014;348:g3668 (Published 24 June 2014)

Safety of pertussis vaccination in pregnant women in UK: observational study
BMJ 2014;349:g4219 (Published 11 July 2014)

Developing World Bioethics – August 2014

Developing World Bioethics
August 2014 Volume 14, Issue 2 Pages ii–viii, 59–110
http://onlinelibrary.wiley.com/doi/10.1111/dewb.2014.14.issue-2/issuetoc

EDITORIAL
Access to Medicines in Developing Countries: Ethical Demands and Moral Economy
Maurice Cassier and Marilena Correa
Article first published online: 17 JUL 2014
DOI: 10.1111/dewb.12066
[No abstract[

Access to Medicines and Distributive Justice: Breaching Doha’s Ethical Threshold (pages 59–66)
Rachel Kiddell-Monroe
Article first published online: 21 APR 2014 | DOI: 10.1111/dewb.12046
Abstract

The Right to Health and Medicines: The Case of Recent Multilateral Negotiations on Public Health, Innovation and Intellectual Property (pages 67–74)
German Velasquez
Article first published online: 12 MAY 2014 | DOI: 10.1111/dewb.12049
Abstract

JAMA: HIV

JAMA
July 23/30, 2014, Vol 312, No. 4
http://jama.jamanetwork.com/issue.aspx

Viewpoint | July 23/30, 2014
An HIV Cure: Feasibility, Discovery, and Implementation
Anthony S. Fauci, MD1; Hilary D. Marston, MD, MPH1; Gregory K. Folkers, MS, MPH1
Author Affiliations
JAMA. 2014;312(4):335-336. doi:10.1001/jama.2014.4754
Initial text
The discovery and deployment of antiretroviral therapy (ART) for human immunodeficiency virus (HIV) infection is one of the most extraordinary achievements in recent biomedical history. Between 1996 and 2012, ART averted an estimated 6.6 million AIDS-related deaths worldwide.1 For HIV-infected individuals with access to ART, life expectancy at diagnosis now approximates that of uninfected individuals—a remarkable feat. These extraordinary successes, however, are tempered by the necessity of lifelong drug therapy. Many patients struggle with adherence in the face of competing priorities, both within the clinical context (comorbidities) and beyond (food insecurity, housing, substance abuse, and other challenges). The drugs can cause health issues in the form of cumulative toxicities. Nations and health systems struggle to find the resources needed to provide long-term therapy. The challenges of resistance and drug-drug interactions add considerable complexity to the provision of care….

Realization of an AIDS-Free Generation: Ensuring Sustainable Treatment for Children
Shirin Heidari, PhD; Lynne M. Mofenson, MD; Linda-Gail Bekker, MBChB, FCP, PhD

Maximizing Benefits of New Strategies to Prevent Mother-to-Child HIV Transmission Without Harming Existing Services
Benjamin H. Chi, MD, MSc; Harsha Thirumurthy, PhD; Jeffrey S. A. Stringer, MD
Editorials
Integrating HIV Prevention Into Practice
Bradley M. Mathers, MBChB, MD; David A. Cooper, MD, DSc

HIV/AIDS: Gaining Ground and Forging Forward
Jeanette M. Smith, MD

Special Communication
HIV Prevention in Clinical Care Settings: 2014 Recommendations of the International Antiviral Society–USA Panel
Jeanne M. Marrazzo, MD, MPH; Carlos del Rio, MD; David R. Holtgrave, PhD; Myron S. Cohen, MD; Seth C. Kalichman, PhD; Kenneth H. Mayer, MD; Julio S. G. Montaner, MD; Darrell P. Wheeler, PhD, MPH; Robert M. Grant, MD, MPH; Beatriz Grinsztejn, MD, PhD; N. Kumarasamy, MD, PhD; Steven Shoptaw, PhD; Rochelle P. Walensky, MD, MPH; Francois Dabis, MD, PhD; Jeremy Sugarman, MD, MPH; Constance A. Benson, MD

Antiretroviral Treatment of Adult HIV Infection: 2014 Recommendations of the International Antiviral Society–USA Panel
Huldrych F. Günthard, MD; Judith A. Aberg, MD; Joseph J. Eron, MD; Jennifer F. Hoy, MBBS, FRACP; Amalio Telenti, MD, PhD; Constance A. Benson, MD; David M. Burger, PharmD, PhD; Pedro Cahn, MD, PhD; Joel E. Gallant, MD, MPH; Marshall J. Glesby, MD, PhD; Peter Reiss, MD, PhD; Michael S. Saag, MD; David L. Thomas, MD, MPH; Donna M. Jacobsen, BS; Paul A. Volberding, MD

Research Letter
Trends in Diagnoses of HIV Infection in the United States, 2002-2011
Anna Satcher Johnson, MPH; H. Irene Hall, PhD; Xiaohong Hu, MS; Amy Lansky, PhD, MPH; David R. Holtgrave, PhD; Jonathan Mermin, MD, MPH

Transformation of HIV from pandemic to low-endemic levels: a public health approach to combination prevention

The Lancet
Jul 19, 2014 Volume 384 Number 9939 p207 – 280
http://www.thelancet.com/journals/lancet/issue/current

Transformation of HIV from pandemic to low-endemic levels: a public health approach to combination prevention
Alexandra Jones LLM a, Ide Cremin PhD b, Fareed Abdullah FCPHM(SA) c, Prof John Idoko MD d, Peter Cherutich MPH e, Nduku Kilonzo PhD f, Prof Helen Rees MB BCHIR g, Prof Timothy Hallett PhD b, Kevin O’Reilly PhD h, Florence Koechlin MIA h, Bernhard Schwartlander PhD i, Barbara de Zalduondo PhD j, Susan Kim JD a, Jonathan Jay JD a, Jacqueline Huh BA a, Prof Peter Piot PhD k, Dr Mark Dybul MD a
Summary
Large declines in HIV incidence have been reported since 2001, and scientific advances in HIV prevention provide strong hope to reduce incidence further. Now is the time to replace the quest for so-called silver bullets with a public health approach to combination prevention that understands that risk is not evenly distributed and that effective interventions can vary by risk profile. Different countries have different microepidemics, with very different levels of transmission and risk groups, changing over time. Therefore, focus should be on high-transmission geographies, people at highest risk for HIV, and the package of interventions that are most likely to have the largest effect in each different microepidemic. Building on the backbone of behaviour change, condom use, and medical male circumcision, as well as expanded use of antiretroviral drugs for infected people and pre-exposure prophylaxis for uninfected people at high risk of infection, it is now possible to consider the prospect of what would be one of the most remarkable achievements in the history of public health: reduction of HIV transmission from a pandemic to low-level endemicity.

Nature Editorials: Polio Eradication, Pakistan

Nature
Volume 511 Number 7509 pp263-376 17 July 2014
http://www.nature.com/nature/current_issue.html

Editorial
Sharing
Within reach – A redoubling of efforts should swiftly eradicate polio from its last strongholds.
16 July 2014
The global effort to eradicate poliomyelitis has been spectacularly successful, eliminating 99% of cases in its 26-year history. But that progress has begun to unravel in the past 18 months, with outbreaks in east and west Africa and in the Middle East. The lesson is clear: as long as the virus is allowed to persist in the three countries in which it remains endemic — Pakistan, Afghanistan and Nigeria — exports of the disease will continue to affect other countries. A determined effort is needed to eradicate the virus from these endemic countries, and fast.

The worsening situation meant that in May, the World Health Organization (WHO) declared polio a public-health emergency of international concern. This allowed it to impose a requirement that all travellers entering or leaving Pakistan, Cameroon, Syria and Equatorial Guinea — the countries currently exporting polio — must have up-to-date polio vaccinations. And it strongly recommended the same for other nations with ongoing polio outbreaks. The WHO also requires the governments of affected countries to declare that polio constitutes a national public-health emergency.

It is too soon to tell how well countries will enforce the travel restrictions or how effective they will be. But the WHO’s declaration has another, and arguably more important, potential impact. It has greatly heightened public and political awareness of the global polio threat. The move could yet shame those nations with weak control efforts into doing better. Ultimately, political will, through every level of government right down to the local level, is crucial if eradication efforts are to succeed.

The setbacks have reignited scepticism among some critics of the multibillion-dollar global effort, which has repeatedly missed its own deadlines for worldwide eradication — the first such deadline was set for 2000. But this must not obscure the fact that impressive gains have been made, so much so that at the end of 2012, global polio eradication truly seemed within reach. It is important to turn the current situation around quickly, consolidate those gains, and condemn polio to the history books.

There is cause for optimism. In Afghanistan, the virus has been wiped out from many areas where it was previously rampant, with cases now restricted mostly to the northeast, where polio is imported from across the border with Pakistan. Afghanistan is expected to become polio-free perhaps as soon as year’s end. Nigeria has also improved its eradication efforts, resulting in a sharp drop in case numbers. Eradication there is in sight, although a current worsening of the country’s political and security tensions risks undoing the progress. Pakistan, despite a lacklustre control effort, has also shrunk the geographical range of the virus.

The global-eradication effort — despite some shortcomings — has a good track record of successfully fighting sporadic flare-ups. There is every reason to believe that the current spate of outbreaks will be contained (although war-torn Syria could remain problematic).

The big challenge is to conquer the virus in the endemic countries that are fuelling exports of the disease — and above all in Pakistan. A report released in May by the Independent Monitoring Board of the Global Polio Eradication Initiative puts it bluntly: “Pakistan’s situation is dire. Its program is years behind the other endemic countries.” Unless matters change, the report concludes, the country is “firmly on track to be the last polio-endemic country in the world”.

That damning indictment needs to be heard and responded to at every level of Pakistani society. The country faces many obstacles — but so too did the other countries that nonetheless have succeeded in eradicating polio. There is no excuse for Pakistan not to do so. Its government must pull out all the stops to act swiftly and decisively. As the report rightfully argues, ultimate responsibility for Pakistan’s bungled polio efforts lies with its authorities: “If the country’s leaders were to truly and wholly take on the mission of wiping polio from their borders, what now seems to some an impossible dream would fast become reality.”

Another barrier to eradication is societal resistance to vaccination, rooted, for example, in local distrust of immunization campaigns and unfounded concerns that it conflicts with religious beliefs. Polio has spread to Waziristan in northern Pakistan, a stronghold of the Taliban, who have banned vaccinations. Vaccinators have also been murdered.

In the past few months, international Islamic scholars and bodies — including the newly formed Islamic Advisory Group on Polio Eradication — have to their credit spoken out to condemn attacks on polio workers, and to emphasize that polio vaccination is compatible with Islam, denouncing those who claim otherwise. Resistance and suspicion of vaccines will always be present, but religious leaders can help by reiterating these messages to local populations.

Pakistan’s situation is exacerbated by the Taliban’s stubborn blocking of polio vaccinations, ostensibly in opposition to US drone strikes. But polio has no religion. It respects no political affiliation. For the benefit of all, every effort must be made to overcome residual resistance to vaccination and to root out the virus from its last strongholds.

.
Nature | Comment
Sharing
Infectious disease: Polio eradication hinges on child health in Pakistan
Zulfiqar Ahmed Bhutta
16 July 2014
Boosting basic medical services and routine immunizations — not travel vaccinations — is the key to ending polio worldwide, says Zulfiqar Ahmed Bhutta.
Until about a year ago, a world free of poliomyelitis seemed to be imminent. In 1988, about 350,000 people in 125 countries became paralysed by the virus. Last year, only 406 cases were reported, with 160 of them in just a few areas of the three countries where polio remains endemic: Afghanistan, Nigeria and Pakistan. In April 2013, charities and governments pledged US$4 billion to a six-year plan developed by the World Health Organization (WHO) to eradicate polio. In March, after India had gone three years with no new cases, the WHO certified its southeast Asia region (which does not include Afghanistan and Pakistan) as polio-free.

But in May, the WHO declared polio an international public-health emergency, particularly because of the high risk of international spread from Pakistan, Cameroon and Syria (see go.nature.com/7z3efj). Disrupted vaccination programmes in war-torn places are partly to blame.

Confronted by this, the WHO took an unprecedented step: it called for mandatory polio vaccination for everyone travelling to or from Pakistan, Syria and Cameroon, and encouraged travel vaccinations for Afghanistan, Nigeria and others1. Formal international travel restrictions for Pakistan began on 1 June. Analyses in the past few years show2 that symptom-free adults transmit polio at surprisingly high rates. However, computer modelling described3 earlier this month suggests that immunizing adults to control an outbreak is less effective than previously believed.

In my view, vaccinating travellers will be ineffective and it could make polio harder to eliminate in the poor and conflict-ridden parts of Pakistan. It is largely here that the final battle to eradicate polio from the world will be won or lost.

Cases of polio in Pakistan increased from 18 in the first six months of 2013 to 88 in the first half of 2014 (ref. 4). Of these, 75% were in the regions known as the Federally Administered Tribal Areas (FATA) in the northwest (see ‘Dangerous rebound’). Here, access for polio-vaccination teams is severely restricted by conflict and insecurity.

Since mid-June, the situation has worsened. In the wake of government military action against Taliban insurgents, more than 800,000 people from Waziristan in the FATA have been displaced to neighbouring parts of Pakistan and Afghanistan. Instead of focusing on the vaccination of international travellers, Pakistan, the WHO and immunization services should provide immediate health care to displaced families and others in these high-risk areas.

Precious doses
Federal and provincial governments in Pakistan have scrambled to set up vaccination points at all ports and airports, and at more than 130 public hospitals. The government of Punjab, Pakistan’s richest and most populous province, also rushed to impose vaccination requirements for the main routes of entry. The federal government made polio vaccination mandatory at major entry and exit points in the FATA, especially in North Waziristan, although much of the long, troubled border with Afghanistan is unpatrolled.

Official sources estimate that more than 10 million doses are needed just for the air travellers entering or exiting Pakistan each year, including the roughly 7 million Pakistani citizens who work overseas, mostly as labourers in the Middle East. The donor community has provided 200,000 doses of injectable polio vaccine for refugees, but no further financial support has been pledged for more doses or for trained staff to perform vaccinations and issue certificates to adult travellers at public hospitals.
So far, the only service offered for free to travellers is the oral vaccine from the supplies of national polio programmes. (Some 300 million doses of oral polio vaccine, mostly furnished by the United Nations children’s charity UNICEF, are needed annually to vaccinate young children in Pakistan.) Pakistan’s army requested 60,000 doses of inactivated injectable polio vaccine as a priority for its troops. Adults must buy this type of vaccine privately at a cost of $4.30 per dose — a huge expense in an area where the average monthly income is about $100. Newspapers report that getting a vaccination certificate is as difficult and expensive as getting a visa. An industry of fake certification could emerge.

There is no precedent to predict how well these travel restrictions will work. I travelled out of Karachi airport on 6 and 15 June. Although vaccination counters had been set up, I saw no queues of travellers waiting to receive polio vaccines, and no one asked me for a vaccination card at any of the multiple checkpoints. Furthermore, polio transmission from Pakistan to Afghanistan occurs mostly across an unregulated border.

Meanwhile, Pakistan’s efforts to vaccinate young children have fallen behind. Some of the blame can be pinned on the ill-planned abolition of its ministry of health in 2011 and the subsequent devolution of health services to the provinces. Although the ministry was reinstated last year and federal polio efforts are now back in operation, they are still weak.

That said, Pakistan deserves much more credit than it has received for its past work to eradicate polio, especially in its troubled tribal regions: it has staged more than 130 national and regional polio-immunization efforts since it began house-to-house vaccination campaigns in 2000.

But the emphasis on polio, to the neglect of other health services, has long fuelled beliefs that polio immunization is an external initiative operating for outsiders’ benefit. Anti-Western sentiment has led to repeated attacks on polio-eradication workers, volunteers and security personnel; more than 80 have been killed since December 2012. This year, polio teams have been hit by roadside bombs and by gunmen on motorcycles. In March, a Pakistani polio worker was kidnapped and shot.

Resistance to polio campaigns is more entrenched and violent in Pakistan than in most other countries. Disastrously, mobile-vaccination teams came under more suspicion than ever5 after it emerged that the US Central Intelligence Agency had staged a fake hepatitis B vaccination project in the Pakistani city of Abbottabad in 2011 to try to trace Osama bin Laden.

Although international Islamic scholars have spoken up for polio eradication, support for it from local religious and society leaders on the ground has been, at best, lukewarm. In the 1980s and 90s, warring factions in Latin America and in Africa agreed to ‘days of tranquility’ to permit mass polio immunizations. In Pakistan, by contrast, a handful of Taliban leaders in the tribal areas of North Waziristan and the Khyber Agency have, since mid-2012, denied entry to vaccination teams as a protest against US drone strikes.

Pakistani army moved to provide security to vaccination teams in the FATA, but it has not offered support to other mainstream health workers. This and the hastily imposed travel regulations will only give credence to claims that polio eradication is part of a foreign agenda.

Prescription package
Providing polio vaccines as part of a package of health services is a better way to engage local communities and religious leaders than through a narrow, polio-specific programme. Nigeria and Afghanistan have made remarkable progress in reaching difficult populations in this way, and cases dropped by about 60% in both nations from 2012 to 20134. The Taliban do not actively keep children from being immunized for measles or from receiving care for diarrhoea or malnutrition.
Currently, Pakistan has one of the highest rates of child mortality in south Asia6. Children face much bigger health threats than polio. But immunization services for major childhood diseases such as diphtheria, tetanus and measles remain plagued with inefficiencies, poor oversight and a shortage of resources.

Full immunization rates for children in the country were last year estimated at 54% with wide variations across the country7, compared to more than 95% in nearby Bangladesh. The figures for Pakistan may even be an overestimate: the survey excluded the FATA and vulnerable populations in mega-cities. In a household survey conducted this year, my colleagues and I found that 25% of children under five years in the urban slums of Karachi were not vaccinated for any childhood disease; the same was true for 64% of children in a relatively peaceful district of the FATA.

The time to act is now. The military offensive in North Waziristan has, paradoxically, opened up opportunities to provide health services to children from the FATA through care for displaced families. This could contribute to building community support and to re-establish the rule of law in conflict-ridden areas once people return. Ongoing support will be necessary to eradicate polio: children require multiple doses of vaccine to build immunity.

I fervently hope that the government and concerned agencies will devote their energies to scaling up full immunization efforts in these displaced and marginal populations, rather than diverting resources to international travellers. This is a chance to eradicate polio from the planet.

Review: Intranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives

Pharmaceutics
Volume 6, Issue 3 (September 2014), Pages 354-
http://www.mdpi.com/1999-4923/6/2

Review: Intranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives
by Yingying Xu, Pak-Wai Yuen and Jenny Ka-Wing Lam
Pharmaceutics 2014, 6(3), 378-415; doi:10.3390/pharmaceutics6030378
Received: 18 February 2014; in revised form: 20 June 2014 / Accepted: 24 June 2014 / Published: 10 July 2014
Abstract
Intranasal delivery of DNA vaccines has become a popular research area recently. It offers some distinguished advantages over parenteral and other routes of vaccine administration. Nasal mucosa as site of vaccine administration can stimulate respiratory mucosal immunity by interacting with the nasopharyngeal-associated lymphoid tissues (NALT). Different kinds of DNA vaccines are investigated to provide protection against respiratory infectious diseases including tuberculosis, coronavirus, influenza and respiratory syncytial virus (RSV) etc. DNA vaccines have several attractive development potential, such as producing cross-protection towards different virus subtypes, enabling the possibility of mass manufacture in a relatively short time and a better safety profile. The biggest obstacle to DNA vaccines is low immunogenicity. One of the approaches to enhance the efficacy of DNA vaccine is to improve DNA delivery efficiency. This review provides insight on the development of intranasal DNA vaccine for respiratory infections, with special attention paid to the strategies to improve the delivery of DNA vaccines using non-viral delivery agents

TRANSVAC workshop on standardisation and harmonisation of analytical platforms for HIV, TB and malaria vaccines: ‘How can big data help?’

Vaccine
Volume 32, Issue 35, Pages 4365-4598 (31 July 2014)
http://www.sciencedirect.com/science/journal/0264410X/32/34

TRANSVAC workshop on standardisation and harmonisation of analytical platforms for HIV, TB and malaria vaccines: ‘How can big data help?’
Pages 4365-4368
Céline Dutruel, Jelle Thole, Mark Geels, Hans-Joachim Mollenkopf, Tom Ottenhoff, Carlos A. Guzman, Helen A. Fletcher, Odile Leroy, Stefan H.E. Kaufmann
Abstract
Highlights
:: Challenges of performing global analyses were discussed at a TRANSVAC workshop.
:: Study group sizes and numbers to be defined in order to compare studies.
:: Bio-repository for sample storage to be created for future analysis.
:: Influence of the environment on the host responses to be considered.
:: Internal standards to be established for molecular and immunological profiling.

Comparison of self-report influenza vaccination coverage with data from a population based computerized vaccination registry and factors associated with discordance

Vaccine
Volume 32, Issue 35, Pages 4365-4598 (31 July 2014)
http://www.sciencedirect.com/science/journal/0264410X/32/34

Comparison of self-report influenza vaccination coverage with data from a population based computerized vaccination registry and factors associated with discordance
Original Research Article
Pages 4386-4392
Rodrigo Jiménez-García, Valentín Hernandez-Barrera, Cristina Rodríguez-Rieiro, Pilar Carrasco Garrido, Ana López de Andres, Isabel Jimenez-Trujillo, María D. Esteban-Vasallo, Maria Felicitas Domínguez-Berjón, Javier de Miguel-Diez, Jenaro Astray-Mochales
Abstract
Objectives
We aim to compare influenza vaccination coverages obtained using two different methods; a population based computerized vaccination registry and self-reported influenza vaccination status as captured by a population survey.
Methods
The study was conducted in the Autonomous Community of Madrid (ACM), Spain, and refers to the 2011/12 influenza vaccination campaign.
Information on influenza vaccination status according to a computerized registry was extracted from the SISPAL database and crossed with the electronic clinical records in primary care (ECRPC). Self-reported vaccine uptake was obtained from subjects living in the ACM included in the 2011–12 Spanish National Health Survey (SNHS). Independent study variables included: age, sex, immigrant status and the presence of high risk chronic conditions. Vaccination coverages were calculated according to study variables. Crude and adjusted prevalence ratios were computed to assess concordance.
Results
The study population included 5,245,238 adults living in the ACM in year 2011 with an individual ECRPC and 1449 adult living the ACM and interviewed in the SNHS from October 2011 to June 2012. The weighted vaccination coverage for the study population according to self-reported data was 19.77% and 15.04% from computerized registries resulting in a crude prevalence ratio (cPR) of 1.31 (95% CI 1.20–1.44) so self-reported data significantly overestimated 31% the registry coverage. Self-reported coverages are always higher than registry based coverages when the study population is stratified by the study variables. Self-reported overestimation was higher among men than women, younger age groups, immigrants and those without chronic conditions. Both methods provide the most concordant estimations for the target population of the influenza vaccine.
Conclusions
Self-report influenza vaccination uptake overestimates vaccination registries coverages. The validity of self-report seems to be negatively affected by socio-demographic variables and the absence of chronic conditions. Possible strategies must be considered and implemented to improve both coverage estimation methods.

Achieving high uptake of human papillomavirus vaccine in Cameroon: Lessons learned in overcoming challenges

Vaccine
Volume 32, Issue 35, Pages 4365-4598 (31 July 2014)
http://www.sciencedirect.com/science/journal/0264410X/32/34

Achieving high uptake of human papillomavirus vaccine in Cameroon: Lessons learned in overcoming challenges
Original Research Article
Pages 4399-4403
Javier Gordon Ogembo, Simon Manga, Kathleen Nulah, Lily H. Foglabenchi, Stacey Perlman, Richard G. Wamai, Thomas Welty, Edith Welty, Pius Tih
Abstract
Background
Cameroon has the highest age-standardized incidence rate of cervical cancer (30/100,000 women) in Central Africa. In 2010–2011, the Cameroon Baptist Convention Health Services (CBCHS) received donated human papillomavirus (HPV) vaccine, Gardasil, from Merck & Co. Inc. through Axios Healthcare Development to immunize 6400 girls aged 9–13 years. The aim was to inform the Cameroon Ministry of Health (MOH) of the acceptability, feasibility, and optimal delivery strategies for HPV vaccine.
Methods and findings
Following approval by the MOH, CBCHS nurses educated girls, parents, and communities about HPV, cervical cancer, and HPV vaccine through multimedia coverage, brochures, posters, and presentations. Because educators were initially reluctant to allow immunization in schools, due to fear of adverse events, the nurses performed 40.7% of vaccinations in the clinics, 34.5% in community venues, and only 24.7% in schools. When no adverse events were reported, more schools and communities permitted HPV vaccine immunization on their premises. To recover administrative costs, CBCHS charged a fee of US$8 per 3-dose series only to those who were able to pay. Despite the fee, 84.6% of the 6,851 girls who received the first dose received all three doses.
Conclusions and lessons learned
With adequate education of all stakeholders, HPV vaccination is acceptable and feasible in Cameroon. Following this demonstration project, in 2014 the Global Access to Vaccines and Immunization (GAVI) Alliance awarded the Cameroon MOH HPV vaccine at a price of US$4.50 per dose to immunize sixth grade girls and girls aged 10 years who are not in school in two districts of Cameroon.